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ABSTRACT
Angiotensin II (Ang II) activates cytosolic phospholipase A2α and releases
arachidonic acid (AA) from tissue phospholipids. AA metabolites mediate or modulate
one or more reno-cardiovascular effects of this peptide and have been implicated in
hypertension. Since AA release is the rate limiting step in eicosanoid production, it is
possible that cPLA2α might play a central role in the development of Ang II-induced
hypertension. To test this hypothesis, we investigated the effect of Ang II infusion for 13
days by micro-osmotic pumps (700 ng/kg/min), on systolic blood pressure and associated
pathophysiological changes in wild type (cPLA2α+/+) and cPLA2α-/- mice. Ang II infusion
increased systolic blood pressure in cPLA2α+/+ but not in cPLA2α-/- mice. Ang II induced
increase in systolic blood pressure was also abolished by the AA metabolism inhibitor,
5,8,11,14-eicosatetraynoic acid in cPLA2α+/+ mice. Ang II infusion in cPLA2α+/+ mice
increased cardiac and renal cPLA2 activity, resulted in cardiovascular and renal
dysfunction, caused cardiovascular remodeling, endothelial dysfunction, increased
vascular reactivity and compromised renal hemodynamics in cPLA2α+/+ mice; these
events were diminished in cPLA2α-/- mice. Ang II also increased cardiac and renal
infiltration of F4/80+ macrophages and CD3+ T lymphocytes, caused cardiac fibrosis and
produced cardiovascular and renal oxidative stress and end organ damage, in cPLA2α+/+
but not cPLA2α-/- mice. Infusion of Ang II increased cardiac ER stress and activity of
ERK1/2 and cSrc in cPLA2α+/+, but not cPLA2α-/- mice. These data suggest that Ang IIinduced hypertension and associated reno-cardiovascular pathophysiological changes are
mediated by cPLA2α activation, most likely through the release of AA and the generation
of pro-hypertensive eicosanoids.
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CHAPTER 1.
1.1

INTRODUCTION

Strategy and Significance

Cardiovascular disease is prevalent in modern societies, and hypertension is the
leading cause of cardiovascular morbidity/mortality. According to the latest AHA
statistics, in the United States, 76.4 million (33.5%) individuals ≥ 20 years of age are
hypertensive, and more than 70% of patients who suffer a heart attack, stroke, or
congestive heart failure are hypertensive.1 Moreover, hypertension is a major risk factor
for ischemic heart disease and renal failure. Clearly, physicians need better approaches to
prevent hypertension-related morbidity and mortality; thus, the focus of this study is to
explore the potential of a promising therapeutic target, i.e., cytosolic phospholipase A2D
(cPLA2D).
cPLA2D is a subset of a large family of phospholipase enzymes that release fatty
acids from the second carbon of phospholipids. Mammals have at least 15 groups of
PLA2 enzymes, which have been classified into four groups based on structure, catalytic
mechanism, localization, and evolutionary relationship: Ca2+-dependent cPLA2D, Ca2+independent PLA2 (iPLA2), secretory PLA2 (sPLA2), and platelet-activating
acetylhydrolases.2 cPLA2D is widely expressed and constitutively active; however,
nanomolar levels of Ca2+ and various mitogen-activated protein kinases and
calcium/calmodulin-dependent kinase II (CAMKII) via phosphorylation regulate cPLA2D
activity.3-6 cPLA2α has been implicated in a number of physiological and
pathophysiological conditions including allergy, asthma, brain ischemia injury, and
arthritis.7
With regard to hypertension and cardiovascular disease, PLA2 activity is
increased in the renal medulla and cortex of stroke-prone, spontaneously hypertensive
rats (SHR),8 and a recent study demonstrated that cPLA2α gene disruption prevented LNG-nitroarginine methyl ester (L-NAME), an inhibitor of nitric oxide synthesis-induced
hypertension.9 But the most compelling reason for focusing on cPLA2α is that this
enzyme is activated by numerous blood pressure (BP) regulating-hormones and is highly
selective for arachidonic acid (AA)-containing phospholipids. Thus, cPLA2α is a major
center of convergence for the transduction of hormone signaling via generation of
eicosanoids, which represent a complex family of AA metabolites that are critically
engaged in BP regulation and end organ damage. In view of the release of AA from
tissue lipids by neuro-humoral agents and AA’s metabolism via multiple pathways into
pro- and anti-hypertensive eicosanoids, it appears that the effect/levels of prohypertensive eicosanoids predominate during hypertension. Importantly, the production
of pro-hypertensive eicosanoids depends upon the release of AA by cPLA2α from tissue
lipids, a rate-limiting step in the synthesis of eicosanoids. Thus, activation of cPLA2α by
angiotensin (Ang) II and other vasoactive agents could be a key step in the development
of hypertension and associated cardiovascular and renal pathophysiology.
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Thus the hypothesis of my study is that Group IV cPLA2α is critical for the
development of Ang II-induced hypertension and its pathogenesis and associated target
organ damage. To test this hypothesis, the following are the aims of this study.
1.2

Specific Aims

1.2.1 Aim 1. To Determine the Contribution of cPLA2α to Ang II-Induced
Hypertension and Associated Cardiovascular Pathophysiology
Rationale: Ang II activates one or more phospholipases. However, AA released in
cardiovascular and renal tissues and infiltration of macrophages is primarily due to
activation of cPLA2D.3,10,11 AA and/or its metabolites activate nicotinamide dinucleotide
phosphate (NADPH) oxidase and generate reactive oxygen species (ROS) in the
cardiovascular system, both of which have been implicated in the development of
hypertension and cardiovascular and renal dysfunction.12-16 These observations, and our
preliminary data that the inhibitor of AA metabolism, 5,8,11,14-eicosa-tetraynoic acid
(ETYA), prevents Ang II-induced increase in systolic blood pressure (SBP) and that
cPLA2D gene disruption in mice minimizes Ang II-induced hypertension, cardiac
dysfunction as determined by echocardiography, and cardiac fibrosis and cardiovascular
oxidative stress as indicated by increased dihydroethidium (DHE) staining have led us to
the following hypothesis:
cPLA2D is critical for the development of Ang II-induced hypertension,
hypertrophy, and activation of NADPH oxidase, generation of ROS, cardiovascular
dysfunction and fibrosis.
1.2.2 Aim 2. To Investigate if cPLA2α Is Essential for Renal Dysfunction and End
Organ Damage Associated with Ang II-Induced Hypertension
Rationale: To determine the role of cPLA2D in renal pathophysiology associated
with hypertension, I have compared the effects of Ang II on kidney structure and function
in cPLA2D+/+ versus cPLA2D-/- mice. The renin-angiotensin system (RAS) plays an
important role in regulating renal function, and alterations in renal function promote
development of hypertension, which in turn leads to renal damage. Although cPLA2D
gene disruption in mice does not alter basal renal function, except in older mice (>40
weeks) that exhibit a urinary concentrating defect, it is not known if cPLA2D contributes
to renal dysfunction, inflammation, and end organ damage associated with Ang IIinduced hypertension. My data shows that cPLA2D gene disruption results in the loss of
cPLA2 expression and, consequently, Ang II-induced phosphorylation and prevents
proteinuria, renal fibrosis, and oxidative stress. Thus, my second hypothesis is:
cPLA2D is crucial for renal dysfunction, activation of NADPH oxidase,
generation of ROS, and end organ damage associated with Ang II-induced hypertension.
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CHAPTER 2.
2.1

LITERATURE REVIEW

Regulation of Arterial Blood Pressure

The main function of the cardiovascular system is to meet the demands of tissue
perfusion by providing oxygen and nutrients and eliminating waste products. These are
achieved by difference in pressures across the arterial and venous network. The driving
force of this blood flow is called mean arterial pressure (MAP), denoted as Pa (arterial
pressure)
Pa = cardiac output (CO) x total peripheral resistance (TPR)
In order to perform the vital function of tissue perfusion, MAP must at all times
be maintained at a high set point of approximately 100 mmHg. This is achieved by two
major regulatory systems: (i) baroreceptor reflex and (ii) renin angiotensin-aldosterone
system.
2.1.1 Baroreceptor Reflex
Baroreceptors play an essential role in stabilizing perfusion pressure during
altered or disturbed circulatory homeostasis by specific neuronal17,18 or hormonal
adjustments19,20 via changes in sympathetic and parasympathetic output signals to the
heart and sympathetic output to the vasculature. These responses are processed by
specialized mechanoreceptors often referred to as stretch receptors located in the aortic
arch and carotid sinus. At resting BP levels, the baroreceptor afferents deliver tonic
excitatory input to the neurons in the nucleus tractus solitarius (NTS)21 where the
glossopharyngeal and vagus nerve fibers synapse. The NTS is the site of afferent
baroreceptor inputs whereas the rostral ventrolateral medulla (RVLM) is the site for
output of the efferent sympathetic nerve activity.22 The RVLM also receives input signals
from other areas that are linked to baroreceptors: the medullary lateral tegmental field23
and the ventrolateral periaqueductal gray.24 The outflow of the neurons of RVLM is
harmonious with cardiac rhythm. Thus, baroreceptor activation decreases the activity of
these neurons. It has been demonstrated that sensitivity of the baroreceptor reflex appears
to be directly related to the neuronal activity within the pressure region of the RVLM.25
An increase in Pa is sensed as an increase in stretch in the blood vessel that results
in an increased firing rate. In order to restore BP to normal, parasympathetic activity
increases and sympathetic activity decreases resulting in a decrease in heart rate and
contractility, and a decrease in venous and arteriolar constriction, together resulting in
decreased CO and TPR and increased unstressed volume. The operating point of reflex
and its sensitivity are the key determinants of baroreceptor function.22 These are often
altered during various physiological and pathophysiological conditions such as
hypertension,26 sleep,27 aging,28 altered thermoregulation,29 and pregnancy.30 In spite of
such a vigilant system, sustained increased or decreased Pa may result in alteration of the
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afferent signal as seen in patients suffering from essential hypertension, wherein the set
point is reset to a higher level of Pa.31
2.1.2

The Renin Angiotensin System
2.1.2.1 The Historic Timeline of the Renin Angiotensin System (RAS)

It wasn’t until Tigerstedt and Bergmann, in 1898 published their study detailing
the existence of renin, a heat labile substance extracted from rabbit renal cortex.32 Their
idea that renin is the humoral pressor agent, was widely criticized by many until in 1934,
when Goldblatt et al. demonstrated that renal ischemia could result in hypertension.32
They further showed that renin, through its proteolytic action, cleaved angiotensinogen, a
short-lived heat labile peptide, to generate angiotensin, which was then called angiotonin
or hypertensin.32 Almost two decades later, Ang I and Ang II were discovered by Skeggs
and colleagues.33 They successfully demonstrated that angiotensin converting enzyme
(ACE) cleaved Ang I to generate Ang II.34 Shortly after, the work of many other
investigators led to the discovery that Ang II also stimulates the release of aldosterone,
the master regulator of Na+-K+ balance,35 and thus evolved the concept of the RAS.
2.1.2.2 The Major Players of the RAS
The discovery of renin as the rate limiting pressor substance gave impetus to
further research that led to the emergence of new frontiers. RAS system has become the
most well studied subject in the field of cardiovascular research and has since been
recognized as the master regulator of BP and fluid homeostasis. The afferent arteriole of
the glomerulus is lined by specialized smooth muscle cells called the juxtaglomerular
(JG) cells that synthesize renin in its preprohormone form. Clevage of 43 amino acids
from its N terminal results in the formation of active renin, an aspartyl protease that is
stored in the granules of the JG cells.36 Renin release is governed by four inter related
factors: 1) changes in perfusion pressure sensed by the renal baroreceptors in the afferent
arteriole, 2) alterations in the NaCl load sensed by the macula densa cells, 3) changes in
sympathetic nerve activity, and 4) negative feedback mechanism by Ang II directly on
the JG cells.37 Renin is not only synthesized by the kidneys but also by adipose tissue,
adrenal gland, ovaries, brain, and possibly heart and the vasculature; the synthesis and
regulation of renin in other tissues is not well understood.36 The action of renin (Figure
2.1) on angiotensinogen, which is produced primarily by the liver to generate the
biologically inert decapeptide Ang I, is the rate limiting step in the RAS cascade. ACE
which is localized mostly in various cell types such as vascular endothelial cells and
microvillar brush border of epithelial cells then hydrolyses Ang I by cleaving the Cterminal dipeptide to form the biologically active and potent vasoconstrictor, Ang II, an
octapeptide. ACE also metabolizes many other peptides including bradykinin and kallidin
to its inactive state.38 It is well-established that Ang II is the most important player of the
RAS; however, there are other metabolites of Ang that serve important biological
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Figure 2.1

Angiotensin metabolism pathway

Reprinted with permission. Conti S, Cassis P, Benigni A. Aging and the reninangiotensin system. Hypertension. 2012;60:878-883.39
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functions too. Ang III, a heptapeptide, formed by the removal of amino acids from the Nterminal of Ang II, present in the central nervous system, may play a role in tonic BP
maintenance and hypertension.40 Further enzymatic degradation of Ang III results in the
generation of Ang IV, a hexapeptide. Not only do the metabolites of Ang II serve specific
function, the peptides generated at the C-terminal in this process by stepwise enzymatic
cleavage also tend to have specific biological activity. One such important fragment
formed is Ang 1-7, generated by the cleavage of Ang II by the carboxypeptidase, ACE 2.
Ang 1-7, by binding to the Mas receptor, acts as a vasodilator and has been implicated in
promoting natriuresis, anti-proliferation and cardio protection.40,41 Thus, the balance
between ACE and ACE 2 is of critical importance in maintaining Ang II levels.42
Of all the components of the RAS, Ang II is the most important effector
responsible for a multitude of physiological and pathophysiological actions. Four Ang
receptors have been discovered so far.41 Most of the effects of Ang II are mediated via
angiotensin type 1(AT1) receptor (R), whereas the AT2R might mediate a counterregulatory mechanism by inhibiting the actions of Ang II.43 The function of AT3R is not
well known, while AT4R is thought to mediate the release of plasminogen activator
inhibitor-1.41
2.1.2.3 Ang II Signal Transduction
Ang II not only plays an important role in regulating cardiovascular and renal
homeostasis, it is also involved in various cardiovascular diseases including hypertension,
atherosclerosis, restenosis and heart failure. In spite of extensive ongoing research, the
contribution of Ang II to these pathologies remains obscure. The functions of Ang II are
mediated by at least two of the four, 7 transmembrane G-protein coupled receptors; AT1
and AT2. Most of the actions of Ang II that are predominantly located in vascular smooth
muscle cells (VSMC) are mediated via AT1R and on activation, promote hypertrophy,
hyperplasia, proliferation and migration of VSMC,44 vasoconstriction, and aldosterone
release.45 Increased Ang II levels results in increased expression of AT1R, however,
sustained or chronic Ang II exposure causes downregulation of the receptors. In spite of
this tight negative feedback regulation, under certain pathological conditions including
hyperlipidemia,46 and hyperinsulinemia,47AT1Rs are upregulated.
On activation by Ang II, AT1R generates second messengers including inositol
triphosphate (IP3), diacylglycerol (DAG), and ROS via its interaction with several
heterotrimeric G proteins. It also activates intracellular protein kinases such as Ser/Thr
kinases, tyrosine kinases, mitogen activated protein kinase (MAPK) family, and protein
kinase C (PKC) isoforms.48-51 Binding of IP3 to its receptors on sarcoplasmic reticulum
results in calcium efflux into the cytoplasm. Ca2+ released, binds to calmodulin and
results in phosphorylation of myosin light chain via activation of myosin light chain
kinase. This promotes interaction between actin and myosin resulting in smooth muscle
cell contraction.52 DAG also activates PKC, which contributes to the Ras/Raf/MEK/ERK
pathway by which Ang II promotes hypertrophy.53 Ang II also phosphorylates PLA2 and
releases AA, which is metabolized to various vasoactive eicosanoids. (discussed later)
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Another important signaling molecule is ROS, generated via NADPH oxidase. In
VSMC, Ang II activates membrane NADPH oxidase to produce ROS via upstream
mediators Src/EGFR/PI3K/Rac-1.54,55 Several biological actions of Ang II-mediated
effects are ROS dependent. One of the most well studied outcomes of Ang II-induced
ROS production is the inactivation of nitric oxide (NO), resulting in endothelial
dysfunction.56,57 It has been reported that ROS can cause inflammation of the vasculature
by recruiting monocytes, macrophages, and T cells at sites of endothelial damage by
promoting release of cytokines and leukocyte adhesion molecules.58
MAPKs have long been identified as players in the Ang II signal transduction
cascade. They have been involved in an array of functions including gene expression,
protein synthesis and metabolism, transport, volume regulation, and growth.59 Studies
have demonstrated that Ang II activates MAPKs such as extracellular signal regulated
kinases (ERK1/2), c-Jun N-terminal kinases (JNK), and p38 that are involved in VSMC
proliferation, differentiation, migration, and fibrosis.60,61 Touyz et al showed that Ang IIinduced VSMC contraction, mediated via ERK signaling may result in increased
intracellular Ca2+.62 Evidence suggests that activation of ERK1/2 and Akt/PKB inhibits
apoptosis63-65 and, through regulation of PHAS-1, is involved in cell growth and protein
synthesis.66 Ang II-induced ERK1/2 activation results in increased gene expression of
anti-apoptotic transcription factors, c-fos and c-jun, that form the AP-1 complex and
promote cell differentiation, migration, and adhesion.67 Enhanced ERK1/2 activation has
been implicated in hypertension and end organ damage.68 In addition to ERK1/2, Ang II
also activates p38 MAPK, implicated in ROS production via stimulation of NADPH
oxidase.69
Non-receptor tyrosine kinases also participate in Ang II-induced cellular effects.
cSrc has emerged as a key second messenger in Ang II-mediated effects. Downstream,
cSrc activates Ras, FAK, JAK/STAT, and PLC-γ and results in sustained Ca2+ release.70
cSrc also plays a role in Ang II-induced focal adhesion complex formation and actin
bundling in VSMC71 and, thus, is responsible for reorganization of the cytoskeleton
matrix leading to remodeling. Stimulation of AT1R also results in activation of the
JAK/STAT pathway, which results in gene transcription of early response genes
including c-fos and myc.71
Receptor tyrosine kinases including platelet derived growth factor (PDGF),
epidermal growth factor (EGF) are also involved in Ang II-induced hypertrophy. PDGFs
have been well documented in the pathogenesis of vascular disease by promoting VSMC
proliferation and migration.72-74 Linseman et al. demonstrated cross talk between AT1R
and PDGF receptor in VSMC. They showed that stimulation of VSMC with Ang II
resulted in phosphorylation of Shc and formation of the Shc-Grb2 complex, which further
activates cSrc75 that has been previously implicated in Ang II-induced contractile
responses.76 Another major mechanism by which Ang II triggers growth related signaling
pathway is transactivation of the EGF receptor in a Src dependent manner that occurs in
the cholesterol rich domains in the caveolae.77,78 This further leads to activation of the
PI3K/PDK1/Akt1 and the Ras/Raf/ERK pathways via HB-EGF-induced dimerization and
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autophosphorylation of EGFR, resulting in growth, hypertrophy, survival, and
inflammation.79
2.2

Pathogenesis of Hypertension

Uncontrolled hypertension results in approximately 7.6 million premature deaths
per year and is now the number one risk factor for cardiovascular deaths1 The prevalence
of hypertension has increased with the increase in life expectancy, more so in developed
nations where the problem seems to be worse compared to developing countries where
only a small fraction of the population develops hypertension. In the United States alone,
50% of the population between 60-70 years old and 75% over the age of 70, suffer from
hypertension.1 Despite an extensive body of evidence and advances in medicine,
hypertension remains a poorly controlled condition. Primary or essential hypertension,
accounts for 95% of all cases of hypertension for which there is no secondary cause.
2.2.1

Renin Angiotensin Aldosterone System

The renin angiotensin aldosterone system (RAAS) (Figure 2.2) is probably the
most powerful hormone system regulating BP. As explained earlier, Ang II is the most
potent vasoconstrictor and plays a role in both the long and short term regulation of BP. It
helps in maintaining acute blood volume and sodium depletion in times of physiological
crisis.80 The long term effects of Ang II on BP are interrelated with volume homeostasis
through direct and indirect effects on the kidney; however, high salt intake can be a major
game changer and can reduce the effectiveness of various RAAS blockers.80 High levels
of Ang II, attenuate the ability of the kidneys to excrete salt and impair pressure
natriuresis, thereby resulting in increased BP to maintain sodium balance.
The mechanisms that mediate the potent anti-natriuretic effects of ANG II include
direct and indirect effects to increase tubular reabsorption as well as renal hemodynamic
effects.81 Volume depletion and/or under perfusion of kidneys such as sodium depletion,
hemorrhage, or heart failure, result in activation of RAAS, which leads to aldosterone
secretion, resulting in salt and water retention by direct effects on hemodynamics and
epithelial transport. Ang II brings about a reduction in renal blood flow and peritubular
capillary hydrostatic pressure and increases peritubular colloid osmotic pressure by
constricting efferent arterioles; these actions result in increased filtration fraction, thus
facilitating an increase in the driving force for fluid reabsorption across tubular epithelial
cells.81 At very low concentrations, Ang II, by acting on the luminal membrane of the
proximal tubules, stimulates Na+-H+ exchanger, and, on the basolateral membrane,
increases the activity of Na+-K+-ATPase, as well as Na+-HCO3 cotransport.81,82 Ang II
also mediates its effects on loop of Henle, macula densa, and distal nephron segments. It
stimulates bicarbonate reabsorption on loop of Henle and promotes Na+-K+-2Cl- transport
in the medullary thick ascending loop of Henle.82,83 In the distal nephron segments, Ang
II facilitates Na+-ATPase activity as well as epithelial Na channel activity in the cortical
collecting ducts.82,83
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Figure 2.2
Interplay of the renin angiotensin aldosterone system in BP
maintenance and homeostasis
Reprinted with permission. Vinay Kumar AKA, Jon C. Aster, Nelson Fausto. Robbins &
Cotran Pathologic Basis of Disease, 8th edn. Saunders, 2009, page 496.84
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Not only does Ang II regulates BP via renal sodium reabsorption, it does so
through its potent ability to cause vasoconstriction that is mostly confined, but not limited
to post glomerular efferent arterioles. Low levels of Ang II produce an increase in
glomerular filtration rate (GFR) by constricting efferent arteriole but high Ang II levels
constrict both efferent and afferent arterioles resulting in a decrease in GFR. During
hemorrhage, when kidney perfusion in threatened, RAAS is activated, to prevent
excessive reduction in BP, and high levels of Ang II constrict both efferent and afferent
arterioles to decrease GFR and renal blood flow.
2.2.2

Aldosterone

Aldosterone, another powerful hormone, is involved in BP regulation via sodium
retention and potassium excretion and thus plays an important role in renal pressure
natriuresis and has functions similar to those of Ang II. The role of aldosterone in human
hypertension has recently gained a lot of attention, because 20% of hypertensive patients
suffer from primary aldosteronism.85 Aldosterone is synthesized within the zona
glomerulosa of adrenal cortex and acts primarily on the principal cells of the distal
tubules, cortical collecting tubules and collecting ducts. Aldosterone binds to
mineralocorticoid receptors (MR) and exerts both genomic and non-genomic effects. It
promotes transcription of certain target genes and stimulates synthesis of Na+-K+-ATPase
pump on the basolateral epithelial membrane and activates amiloride-sensitive sodium
channels on the luminal side of the epithelial membrane,86 which results in increased
sodium current in the principal cells of the cortical collecting tubule and also stimulates
Na+-K+ exchanger.86,87 Low sodium intake triggers increased aldosterone release to curb
sodium loss to prevent reduction in BP and high sodium intake inhibits aldosterone
secretion in an attempt to prevent sodium retention and lower BP. MR antagonism is
emerging as a therapeutic tool for treating hypertension and associated end organ
damage.85
2.2.3

Endothelin

Endothelial dysfunction resulting from an altered balance between endothelial
derived relaxing and contracting factors has been observed in many forms of
experimental and human hypertension. One such potent constricting factor is endothelin
(ET)-1. ET-1 can activate ET type A (ETA) receptor and elicit a hypertensive response or
it can activate ET type B (ETB) receptor and elicit an antihypertensive response, thus, the
nature of response produced by ET depends on the type of receptor it acts on.
Endothelin, via ETA receptor mostly localized on VSMC, produces systemic and
renal vasoconstriction, impairs pressure natriuresis and increases BP and could contribute
to progressive renal injury. ET-1 stimulates contraction of VSMC and mesangial cell
resulting in decreased GFR and renal blood flow and chronic actions of ET-1 may also
lead to renal mesangial cell proliferation, VSMC hypertrophy and remodeling.88,89
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Several studies have shown that ETB activation by ET-1 on the other hand, causes
vasodilation, enhances pressure natriuresis and decreases BP. ETB deficient rats exhibit
severe salt sensitive hypertension90 and mice develop endothelial dysfunction
independent of salt loading.91
2.2.4 Oxidative Stress
It is well established that ROS contributes to the onset and progression of
hypertension and associated cardiovascular pathology.92 The ROS family consists of
many molecules that have varied effects on growth, differentiation, modulation and
breakdown of extracellular matrix, inactivation of antioxidant defense system, and
initiation and maintenance of pro-inflammatory cascades.93-95 Xanthine oxidase,
uncoupling of NO and tetrahydrobiopterin (BH4), and NADPH oxidase are the
important sources of ROS in vascular disease, of which NADPH oxidase derived ROS
plays a major role in Ang II-induced hypertension.16,96-98 The prototypic NADPH oxidase
has three cytosolic subunits (p47 phox, p67 phox, p40phox) and two membrane subunits
(p22 phox and the catalytic subunit gp91 phox) that occur as a heterodimeric
flavoprotein: cytochrome b558.99,100 On stimulation, p47 phox undergoes
phosphorylation, and the cytosolic subunits assemble to form a complex and translocate
to the membrane where it associates with cytochrome b558 to form the active oxidase.
The NADPH oxidase comprises seven members: NOX 1, 2, 3, 4, and 5 and Duox 1, and
2.
Many models of hypertension have demonstrated the link between oxidative
stress and increased BP. It has been shown that in SHRs, increased ROS formation
precedes development of hypertension thus implying that ROS is important for the
development and maintenance of hypertension.101,102 Also in experimental hypertension,
several markers of oxidative stress, such as thiobarbituric acid reactive substances
(TBARS) and F2-isoprostanes are increased.103-105 Many studies have also successfully
demonstrated the involvement of specific subunits of NADPH oxidase in Ang II-induced
hypertension. Ang II infusion failed to induce hypertension, vascular hypertrophy, and
endothelial dysfunction in p47 phox and gp91 phox knockout mice compared to their WT
counterparts.98,106,107 Another study showed that mice treated with (short interfering
RNA) siRNA against renal p22 phox demonstrated blunted hypertension and reduced
ROS formation, implying that p22 phox is essential for Ang II-induced hypertension,108
however, its overexpression did not significantly increase BP but did result in increased
oxidative stress and endothelial dysfunction.109 Pharmacological inhibition of NADPH
oxidase with apocynin, reduced vascular O2 production, prevented cardiovascular
remodeling and attenuated Ang II-induced hypertension.97
2.2.5

Nitric Oxide

Many studies have established that NO-induced arterial vasodilation is impaired
in various models of hypertension110,111 and NO bioavailability plays a major role in
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endothelial dysfunction.112 NO is produced in the vascular endothelin from L-arginine by
endothelial nitric oxide synthase (eNOS). eNOS null mice and inhibition of eNOS by LNAME exhibit severe hypertension,113,114 and administration of L-arginine and BH4,a
cofactor of eNOS, have demonstrated a reduction in BP and improvement in
endothelial function in both animal models and patients.115-118 Nebivolol, a NO
releasing β blocker improves endothelial function by increasing NO bioavailability
not through its β blocking ability.119 The most important cause for decreased
bioavailability of NO is ROS.120 Hypertension, smoking, obesity, and dyslipidemia,
disrupt antioxidant defense mechanisms, such as NO bioactivity, thus resulting in
oxidation of biomolecules that leads to vascular inflammation, and development of
atherosclerosis and cardiovascular diseases.120 A balance between NO bioavailability
and ROS production must at least be maintained if not favored towards NO. A tilt
towards ROS may lead to decreased endothelium-dependent vasodilation, thus
resulting in, or further exacerbating, hypertension.121,122 Many studies have shown that
Ang II decreases NO bioavailability by promoting production of ROS123 and
superoxide dismutase, and antioxidants such as vitamin C restore endothelial function
in both humans and animal models.124,125
2.2.6

Eicosanoids

Eicosanoids (Figure 2.3) generated from AA, released from tissue phospholipids
by the action of one or more phospholipases, mainly PLA2. AA is metabolized by
cyclooxygenase, lipoxygenase and cytochrome P450 monooxygenase into various
vasoactive eicosanoids. These eicosanoids exert pro-hypertensive as well as antihypertensive effects.126-130
2.2.6.1 Cyclooxygenase Derived Eicosanoids
There are at least two forms of COX enzymes: COX-1, the constitutively active
form and COX-2 the inducible form. COX catalyzes the metabolism of AA into
prostaglandin (PG) H2, which by the action of prostacyclin synthase is further converted
to PGI2 (prostacyclin), E2, D2, and F2α. PGH2 is also metabolized by thromboxane (Tx)
A2 synthase to TxA2.
PGE2 and I2 are known to exert anti-hypertensive effects by dilating resistance
vessels, reducing release of norepinephrine (NE), attenuating response to
vasoconstrictors, and promoting salt and water excretion.131 Treatment with COX
inhibitors results in decreased production of PGE2 and I2, leading to increased vascular
resistance, responsiveness to vasoconstrictors including Ang II, and suppression of
pressure natriuresis response,132,133 thereby resulting in increased BP and renal
dysfunction to a greater extent in hypertensive than normotensive states.134 Also, it has
been shown that rats infused with Ang II show an increase in plasma concentration of
derivative of PGI2; 6-keto-PGF1α.135 The general consensus is that PGE2 and I2
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Figure 2.3

Arachidonic acid metabolism

Agonist (Ang II) induced (1) influx of Ca2+ (2) results in translocation of cPLA2α from
cytosol to nuclear envelope (golgi, ER) (3) and undergoes phosphorylation (4) which
increases its hydrolytic activity that results in AA release (5) from tissue phospholipids.
AA is metabolized by cytochrome P450, cyclooxygenase and lipoxygenase to various pro
and anti-hypertensive eicosanoids.
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contribute to anti-hypertensive mechanisms however, this view is somewhat
controversial. These eicosanoids are also known to stimulate renin secretion,136 and, in
some studies, treatment with Cox inhibitors has been shown to lower BP and reduce
plasma renin activity.137 Also it has been demonstrated that PGH2, is a mediator of
endothelium dependent vasoconstriction in arteries of hypertensive animals.138 TXA2, a
powerful vasoconstrictor, is known to serve pro-hypertensive effects, and both TXA2 and
PGH2 receptors may function in concert to stimulate contraction of VSMC, produce renal
vasoconstriction and reduce renal blood flow.127 It has been demonstrated that infusion of
TXA2/PGH2 receptor agonist results in BP elevation,139 while inhibition of thromboxane
synthase lowers BP in certain models of experimental hypertension.140,141
2.2.6.2 Lipoxygenase Derived Eicosanoids
Lipoxygenases (LOX) are a group of non-heme iron containing dioxygenases142
that metabolize AA into 5,- 12,- 15- hydroxyeicosatetraenoic acids (HETE) and different
forms of leukotrienes (LT).143 Many studies have demonstrated the role of 12-HETE in
BP regulation. Some studies suggest its role as an anti-hypertensive eicosanoid, while
others refer it to as pro-hypertensive. 12-HETE has been shown to inhibit renin secretion
in rat renal slices, and inhibition of LOX increases plasma renin activity in rats
suggesting that 12-HETE could serve as a negative regulator of renin.144 However, many
studies have also shown that 12- hydroperoxyeicosatetraenoic acid (HPETE) and 15HPETE (precursors of 12-and 15- HETEs) inhibit prostacyclin synthase,145,146 indicating
its pro-hypertensive function. 12-HETE also mediates Ang II-induced afferent artery
constriction in the kidney. Inhibition of LOX has also been shown to attenuate Ang IIinduced vasoconstriction147 and to reduce BP in SHR.148 Moreover, Ang II has been
shown to increase the protein, as well as mRNA expression, of 12-LOX in VSMC.149 In
various models of hypertension including two-kidney one clip150 and aortic coarctationinduced hypertension,145 an increase in the levels of HETEs has been observed. Thus, it
appears that LOX derived eicosanoids serve a pro-hypertensive function.
2.2.6.3 Cytochrome P450 Monooxygenase Derived Eicosanoids
Until 1981, cytochrome P450s (Cyp 450) were recognized only as enzymes
required for metabolism and detoxification of xenobiotics. The discovery of their role in
the AA cascade opened new vistas, and the diverse nature and functions of the enzyme
was identified. One of the earliest studies, by McGiff and his collaborators, demonstrated
the contribution of renal CYP4A in the pathophysiology of hypertension.151,152 Cyp 450
via its epoxygenases metabolizes AA into biologically active cis-epoxyeicosatrienoic
(EET) acids; 5,6-, 8,9-, 11,12-, 14,15-EETs and via its Z-hydroxylase activity into 19and 20-HETEs.153,154 Subsequent studies recognized EETs in the activation of calcium
sensitive potassium channels, resulting in hyperpolarizing of membrane potential.155
They play a major role in regulating vascular tone, ion transport, proliferation
inflammation, and hemostasis.154,156-158 More recent studies have sketched an anti-
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hypertensive image of EETs. Overexpression of P450 epoxygenases or treatment with
synthetic EETs resulted in upregulation of eNOS via activation of MAPK and PKC
signaling pathways.159 In another long term study, overexpression of CYP2J2 using a
type 8 recombinant adeno-associated virus vector in SHR increased urinary expression of
14,15 EETs, enhanced mRNA expression of atrial natriuretic peptide, decreased BP, and
improved cardiac output. Furthermore, when the specific inhibitor of CYP2J2 was
administered, it blocked this hypotensive effect and attenuated the increase in the levels
of EETs.160 Furthermore, Capdevila et al, demonstrated that Cyp2c44-/- mice on a high
salt diet develop hypertension and exhibit increased epithelial sodium channel (ENaC)
activity,161 thus implying the importance of Cyp2c44 in regulating BP by controlling
ENaC activity.
CYP4A metabolites of AA have been much appreciated as the anti-hypertensive,
anti-inflammatory arm of the AA metabolism cascade; however, studies in our lab have
demonstrated that the effect of Ang II on VSMC migration, proliferation, and
hypertrophy is via AA release and its metabolism to ROS by CYP1B1.162 Moreover,
male Cyp1b1−/− mice infused with Ang II13,14 or treated with deoxycorticosterone acetate
(DOCA)/salt163 are protected against hypertension, endothelial dysfunction, cardiac
hypertrophy, fibrosis, and inflammation. Also, treatment with the inhibitor of CYP1B1,
2, 3′, 4, 5′-tetramethoxystilbene minimizes hypertension caused by Ang II in Cyp1b1+/+
mice.14,164 Moreover, ROS generated via the metabolism of AA by CYP 1B1, via second
messenger systems, ERK1/2, p38 MAPK, and cSrc stimulate VSMC growth, and
contribute to the development of hypertension and associated pathophysiology.162
AA metabolism is also associated with generation of ROS165 that have been
implicated in hypertension.166 Therefore, the balance between pro- and anti-hypertensive
eicosanoids and generation of ROS, would determine the level of BP. Whether AA
metabolites generated via different pathways, following their release by activation of
cPLA2 by Ang II, contribute primarily to pro- or antihypertensive mechanisms, is not
known.
2.2.7

Emerging Concepts of the Immune System in Hypertension

One of the earliest reports demonstrated that lymph node cells from hypertensive
rats, when introduced in normotensive rats, raised their BP.167 Later, it was shown that
nude mice lacking a thymus or thymectomized mice did not exhibit hypertension
following renal infarction.168 Another study demonstrated that SHR that received donor
thymus from Wistar Kyoto rats showed a reduction in BP.169
More recent studies have shown that mice lacking B and T cells (RAG-/-) are
protected against Ang II-induced hypertension, endothelial dysfunction, and superoxide
production compared to wild type (WT) mice, and adoptive transfer of T but not B cells
restored hypertension.170 Ang II infusion in WT mice, resulted in an increase in
circulating levels of CD69+, CCR5+, and CD44high, suggesting the involvement of T cells
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in hypertension.170 Furthermore, Dahl salt sensitive rats deficient in RAG-1 demonstrated
decreased BP, kidney damage, and albuminuria.171
T cells have many subgroups, one of them being CD4+ T cells that include Th1,
Th2, Th17, and T regulatory cells (Tregs).172 Interleukin (IL)-17A, a cytokine released by
Th17 cells, has been implicated in the pathogenesis of many autoimmune and
inflammatory diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis, asthma,
inflammatory bowel disease, and periodontal disease.173,174 Recent studies have
demonstrated the role of Th17 cells in Ang II-induced hypertension. IL-17-/- mice infused
with Ang II demonstrated an initial increase in BP, which dropped after 7 days, and T cell
infiltration that was observed in WT mice was abolished in IL-17-/- mice. Ang II
increased IL-17 protein deposition in the aortic wall of WT mice.175 The involvement of
other cytokines has also been reported. Marko et al, demonstrated that interferon (IFN)-γ
receptor knockout mice are protected against Ang II-induced cardiac hypertrophy,
macrophage and T-cell infiltration, fibrosis, and arrhythmogenic electric remodeling
compared to WT mice. Also the researchers observed reduced renal inflammation,
tubulointerstitial damage, and improved GFR.176 In another study, tumor necrosis factor
(TNF)-α inhibitor etanercept reduced infiltration of inflammatory and immune cells in a
model of Ang II-induced renal damage.177 Zhang et al. presented evidence in both human
and mice demonstrating the role of cytokine IL-6 in Ang II induced hypertension. They
reported a significant increase in IL-6 expression in kidney samples collected from
chronic kidney disease patients with hypertension. They also showed that Ang II is
responsible for IL-6 induction in murine studies and its genetic deletion significantly
reduced hypertension, ET production, renal injury, and fibrosis.178
Patients suffering from AIDS who have a low CD4+ T cell count, show a low
incidence of hypertension, but when treated with aggressive antiretroviral therapy,
develop increased SBP.179 Mycophenolate mofetil, a T-lymphocyte specific
immunosuppressant used to treat psoriasis and rheumatoid arthritis, ameliorates
hypertension in patients, thus suggesting the involvement of the immune system, more so
the role of T cells in hypertension.180
Based on these and other findings, Harrison et al, proposed a model of T cell
mediated immunity in hypertension15 (Figure 2.4), which suggests that hypertensive
triggers such as Ang II, catecholamines, stress, ROS, and a high salt diet via its actions on
the circumventricular organs in the brain, may result in microglial activation, cytokine
production, and increased sympathetic activity resulting in a small elevation in BP (pre
hypertension) which may result in formation of neo antigens. These neo antigens may
further promote T cell activation resulting in T cell infiltration in the vasculature and
kidney, further causing severe hypertension. Thus the evidence presented above strongly
implicates the involvement of the immune system in hypertension.
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Figure 2.4

T cell mediated immunity in hypertension

Reprinted with permission. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ,
Thabet SR, Vinh A, Weyand CM. Inflammation, immunity, and hypertension.
Hypertension. 2011;57:132-140.15
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2.3
2.3.1

Cytosolic Phospholipase A2α

Phospholipases: An Introduction

More than 30 phospholipases that catalyze the hydrolysis of membrane
glycerophospholipids at the sn-2 position, liberating AA, and lysophospholipids have
been discovered so far.181 Based on the evolutionary relationship, structure, function, and
catalytic activity, PLA2 has been classified into sPLA2, cPLA2, iPLA2 also called patatin
like phospholipase domain-containing lipases, and platelet activating factor
acetylhydrolase.2 Hereafter, I shall focus on the role, significance, and function of
cPLA2D in hypertension. Of all the phospholipases, cPLA2D specifically catalyzes the
hydrolysis of phospholipids containing AA.182
2.3.2 Structure
Group IV cytosolic phospholipase A2, an 85 KDa molecule, was first identified in
human platelets in 1986.183 The structure (Figure 2.5) of the enzyme consists of a C2
domain at the N-terminal, composed of eight antiparallel β strands interconnected by six
loops. It contains the Ca2+ binding motif followed by the catalytic domain composed of
14β strands and 13α helices and houses the α/β hydrolase segment, which is conserved
across many lipases.184 Unique to cPLA2α, within the hydrolase segment, lies, the novel
cap region, which also has a lid region. The C2 domain has two Ca2+ binding sites and is
required for its membrane translocation from cytosol to membrane in response to Ca2+
signaling, whereas the catalytic domain contains crucial sites of phosphorylation 185 and
is required for the stable binding of the enzyme to the membrane after [Ca2+]i
decreases.186
2.3.3

Regulation

AA release via the hydrolytic activity of cPLA2α is mediated by two very
important post translation mechanisms: being: increase in [Ca2+]i and
phosphorylation.187,188 During agonist-induced [Ca2+]i increase, two Ca2+ ions bind to
calcium binding loops in the C2 domain.189-192 The electrostatic potential of the surface
exposed calcium binding loops is reduced, this facilitates the penetration of the
hydrophobic residues into the Golgi membrane.193,194 The basic residues in the C2
domain bind to ceramide 1 phosphate, and the catalytic domain positions itself on the
phospholipid membrane, and Ser505on the catalytic domain is phosphorylated by MAPK,
resulting in increased hydrolytic activity of the enzyme. The basic residues in the
catalytic domain bind to phosphatidylinositol 4,5-bisphosphate and stimulate the ability
of the enzyme to release AA.
Both the amplitude and duration of [Ca2+]i are important determinants for
translocation and regulation of cPLA2α activity.195 The initial transient release of Ca2+
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Figure 2.5

Structure of cPLA2α

Reprinted with permission. Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G.
Phospholipase A2 enzymes: physical structure, biological function, disease implication,
chemical inhibition, and therapeutic intervention. Chemical reviews. Oct 12
2011;111(10):6130-6185.196
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from intracellular stores is important for immediate translocation of cPLA2α to Golgi;197
however, the subsequent influx of Ca2+ is required for maintaining the stable binding of
the enzyme to Golgi to release AA.197 The hydrolytic activity of the enzyme is tightly
regulated by phosphorylation (Figure 2.6). Of the three phosphorylation sites, Ser505 is
the best studied. Phosphorylation of Ser505 is not sufficient for the release of AA, but is
important as it enhances membrane binding affinity even at low Ca2+ levels198 and
facilitates AA release. The main function of Ser505 phosphorylation is to induce a
conformation change in the enzyme and to facilitate penetration of the hydrophobic
residues in the active site, even at submicromolar levels of Ca2+.198 Studies have shown
that phosphorylation of Ser505 depends on phosphorylation of Ser515 by CamKII.199
Activation of cPLA2α by CaMKII results in generation of AA metabolites, particularly
HETEs, which in turn by activating ERK1/2, phosphorylates cPLA2α at Ser505 thereby
releasing further AA.200 Another important site of cPLA2α phosphorylation is Ser727 by
MAPK-activated protein kinase.5 It is also a site for binding of the p11anexin, an
inhibitory complex that prevents binding of the enzyme to the Golgi. Phosphorylation of
Ser727 disrupts this interaction and allows enzyme activation.201
2.3.4 cPLA2α in Disease Pathogenesis : Lessons from the Knockout Mouse
cPLA2D has been implicated in the pathogenesis of various inflammatory diseases.
Studies on cPLA2α-/- mice have revealed that stimulus induced production of
prostaglandins and leukotrienes are greatly reduced in inflammatory and noninflammatory cells obtained from these mice.202-205 In an acute respiratory distress
syndrome model, it has been shown that pulmonary edema, neutrophil sequestration and
pulmonary fibrosis are markedly attenuated in cPLA2α-/- mice, and inhibition of cPLA2α
may be the key in treating various pulmonary disorders.206,207 cPLA2α has also been
implicated in multiple sclerosis, an autoimmune, inflammatory demyelinating disease
resulting in motor and sensory defects. Multiple Sclerosis is thought to be mediated by
the Th1/Th17 axis, in which several lipid mediators: PGE2, LTB4 and PAF are
involved.208-212 cPLA2α-/- mice have been shown to be less susceptible than WT mice to
experimental autoimmune encephalomyelitis disease model (animal model for multiple
sclerosis), and pharmacological inhibition of cPLA2α blocked its onset and
progression.213 Myelin oligodendrocyte glycoprotein specific T cells from the knockout
mice revealed that loss of cPLA2α results in deficient production of Th1 cytokines, and
administration of IL-12 (Th1 cytokine) once again makes the mice more susceptible to
the disease, thus suggesting that cPLA2α facilitates the differentiation of T cells towards
Th1 and Th17 phenotypes in autoimmune diseases. PGE2, PGI2 and LTB4 are involved
in collagen-induced arthritis, which is also Th17 dependent; the incidence and severity of
the disease are greatly reduced in cPLA2α-/- mice.214. Also, in a study of post ischemic
brain injury, it was observed that cPLA2α-/- mice had smaller infarcts, less brain edema
and fewer neurological deficits after transient middle cerebral artery occlusion.204. In a
more recent study, Saito et al, demonstrated that disruption of cPLA2α attenuates
myocardial ischemia/reperfusion injury compared to its WT counterparts, partly through
inhibition of TNF-α-mediated pathways.215 Tanaka et al, showed the involvement of
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Figure 2.6

Phosphorylation sites of cPLA2α

Reprinted with permission. Linkous A, Yazlovitskaya E. Cytosolic phospholipase A2 as a
mediator of disease pathogenesis. Cell Microbiol. 2010;12(10):1369-1377.7
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endothelial cPLA2α in L-NAME-induced hypertension.9 All the above findings suggest
the interplay of cPLA2 with the immune system in various disease pathologies. cPLA2
seems to act as a catalyst in disease pathogenesis and progression; thus, cPLA2 inhibition
may be the key in treating hypertension, which is now being recognized as an immune
system driven disease as discussed above.
Therefore, based on the above review of the literature, it is possible that cPLA2α,
which is highly selective in releasing AA, might function as the major center of
convergence for the transduction of Ang II signaling to produce pro-hypertensive
eicosanoids and ROS. These would, in turn, result in development of hypertension and
associated cardiovascular and renal dysfunction and pathophysiological changes
including activation of immune system, inflammation, and end organ damage. Thus, this
central hypothesis is the major objective of my thesis, to test this hypothesis; I have
investigated the effect of cPLA2D gene disruption in mice on Ang II-induced
hypertension and associated cardiovascular and renal function and pathogenesis.
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CHAPTER 3.
3.1

METHODOLOGY
Animals

Experiments were performed according to protocols approved by our Institutional
Animal Care and Use Committee in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. cPLA2α-/- mice on a BALB/c
background were generated as described204 and provided by Dr. Joseph V. Bonventre at
Brigham and Women's Hospital, Boston, MA. Homozygotes (cPLA2α-/-) were interbred
in our facility, and their genotypes were regularly confirmed by polymerase chain
reaction analysis. WT male BALB/c mice (cPLA2α+/+) used in this study were purchased
from Charles River Laboratories, Inc., Wilmington, MA. All animals were 20-30 g and
approximately 10 weeks of age at the beginning of the experiment.
3.2

Ang II-Induced Hypertension in cPLA2α+/+and cPLA2α -/- Mice

Mice were anesthetized with 1.5% isofluorane to implant micro-osmotic pumps
(Alzet®, Cupertino, CA; model 1002) subcutaneously to infuse Ang II (700 ng/kg/min)
or vehicle (0.9% saline) for 2 weeks, and BP was measured once a week by the
noninvasive tail cuff method (Kent Scientific, Torrington, CT; model XBP 1000). Prior
to implanting the pumps, mice were acclimated twice to the BP measuring device, with 5
days between measurements. These measurements were also confirmed by instrumenting
the mice with a radio telemetry device (TPA-C10, Data Sciences International, St. Paul,
Minnesota) as described previously.216 BP was recorded every third day. In another
series, cPLA2α+/+ mice were infused with Ang II and injected i.p. with inhibitor of AA
metabolism, 5,8,11,14-eicosatetraynoic acid (ETYA) (50 mg/kg/3day) (BML-ET0040020, Enzo Lifesciences, NY). At the end of the experiment, the mice were euthanized
with a cocktail of ketamine (100 mg/kg), xylazine (10mg/kg), and acepromazine
(3mg/kg) i.p., and their tissues were harvested.
3.3
3.3.1

Ultra Sound Imaging and Analysis

Echocardiography

On the 12th day of the study, mice were anesthetized with 1.5% isoflurane, core
body temperature was maintained at 37°C, and heart rate and respiration were
continuously monitored with a pulse oximeter. Echocardiography was performed as
described217 by using the Vevo 2100 (VisualSonics, Inc., Toronto, Canada). Briefly, Mmode and B-mode images in the parasternal long-axis and the left ventricular (LV) shortaxis views at the mid papillary level were taken. Measurements were averaged from three
consecutive beats. M-mode images were used to calculate various parameters of cardiac
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function including ejection fraction (EF), fractional shortening (FS), stroke volume (SV),
cardiac output (CO), and LV mass.
3.3.2

Pulsed Wave Doppler to Measure Renal Hemodynamics

On the 12th day of the study, mice were anesthetized with 1.5% isoflurane, core
body temperature was maintained at 37°C, heart rate and respiration was continuously
monitored with pulse oximeter. Imaging was performed using the Vevo 2100
(VisualSonics Inc Toronto, Canada). Briefly, mice were placed on the platform in supine
position. Long axis of the micro scan transducer was placed on the lateral side, aligned
perpendicular to the long axis of the animal. M-mode and B-mode images were taken.
The Right Renal Artery Peak Systolic Velocity (RRA PSV), Right Renal Artery Lowest
Diastolic Velocity (RRA LDV), Right Renal Artery Velocity Time Integral (RRA VTI)
were measured to calculate :Renal Artery Pulsatility Index: (RRA PSV-RRA LDV)/RRA VTI, mean velocity
Renal Artery Resistive Index: (RRA PSV-RRA LDV)/RRA PSV.
Measurements were averaged from 3 consecutive waveforms.
3.4

Immunohistochemistry

Immunohistochemical analysis for α-smooth muscle actin (SMA) and
transforming growth factor β (TGF-β) was performed to determine the extent of
interstitial fibrosis as previously described.218 Also, tissue sections were processed for
infiltration of CD3+ T cell and F4/80+ monocyte/macrophage. The hearts, thoracic aortas
and kidneys were dissected free and placed in Optimal Cutting Temperature (OCT)
compound (Sakura Finetek USA, Inc., Torrance, CA). Serial transverse cryosections (8μm thick) were cut at -20°C with a Leica Cryostat CM1850 (Leica Microsystems, Inc.,
IL). For α-SMA and TGF-β staining, sections were fixed in formalin for 10 min followed
by three washes in PBS to remove the mounting medium, after which they were allowed
to incubate in 0.3% hydrogen peroxide for 10 min to block endogenous peroxidase
activity. The sections were then rinsed once in PBS and blocked in 5% BSA for 30 min.
Sections were incubated with their respective primary antibodies overnight at 4ιC. All
antibodies were diluted in background reducing diluent (Cat #S3022, Dako, CA). Next
day, sections were washed three times in PBS and incubated with anti-mouse IgG
peroxidase-conjugated secondary antibody for 1 h, washed three times in PBS, and
incubated in diaminobenzidine (Cat #D4293, Sigma Aldrich) that was prepared according
to manufacturer’s instructions, and the tissue sections were then washed with deionized
distilled water (ddw). For staining CD3+ and F4/80+ cells, tissue sections were fixed in
cold acetone after which they were allowed to air dry 5-10 min to facilitate complete
removal of acetone (sections should appear opaque white). Sections were then washed,
followed by the steps described above (Table 3.1 contains detailed conditions). All
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Table 3.1.
Antibody
α-SMA
TGF-β
CD3
F4/80
PLCβ
PLD1
PLD2
AT1
AT2
MAS
ACE
P-cPLA2
cPLA2
P-ERK1/2
ERK1/2
P-Src
c-Src
β-actin

List of antibodies and specific conditions
Application
IHC
IHC
IHC
IHC
WB
WB
WB
WB
WB
WB
WB
WB
WB
WB
WB
WB
WB
WB

Primary Antibody
Cat #
Dilution
Sigma A2547
1:400
Santa Cruz sc-146
1:400
Abcam ab5690
1:100
AbDSerotec MCA497R
1:50
Santa Cruz sc-205
1:500
Gift **
1:500
Gift**
1:500
Santa Cruz sc-1173
1:500
Santa Cruz sc-9040
1:1000
Santa Cruz sc-135063
1:500
Santa Cruz sc-23908
1:500
Cell Signaling cs-2831
1:1000
Santa Cruz sc-454
1:1000
Cell Signaling cs-9106
1:1000
Cell Signaling cs-9102
1:1000
Cell Signaling cs-2101
1:1000
Santa Cruz sc-8056
1:1000
Santa Cruz sc-47778
1:10000

Blocking Buffer
Host
Mouse
Rabbit
Rabbit
Rat
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Mouse
Rabbit
Mouse
Mouse
Rabbit
Rabbit
Mouse
Mouse

5% BSA
Goat normal serum
5% BSA
Rabbit normal serum
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA
5% BSA

** Dr. Sylvain G. Bourgoin, Centre Hospitalier de l'Université Laval, Québec, Canada
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Secondary Antibody
Cat #
Dilution
A3682
1:150
Vectastain ABC kit PK6101
Abcam ab97051
1:100
AbD Serotec STAR72
1:50
ECL Rabbit IgG NA934V
1:2000
ECL Rabbit IgG NA934V
1:1000
ECL Rabbit IgG NA934V
1:1000
ECL Rabbit IgG NA934V
1:1000
ECL Rabbit IgG NA934V
1:1000
ECL Rabbit IgG NA934V
1:1000
ECL Mouse IgG NA931
1:1000
ECL Rabbit IgG NA934V
1:2000
ECL Mouse IgG NA931
1:2000
ECL Mouse IgG NA931
1:2000
ECL Rabbit IgG NA934V
1:2000
ECL Rabbit IgG NA934V
1:2000
ECL Mouse IgG NA931
1:2000
ECL Mouse IgG NA931
1:2000

sections were counterstained with hematoxylin, dehydrated, mounted, and viewed with
an Olympus® inverted system microscope (Olympus America, Inc., model BX41) and
photographed with a SPOT™ Insight™ digital camera (Diagnostic Instruments, Inc.,
model Insight 2MP Firewire).
3.5

Collagen Accumulation

Masson’s trichrome staining (Cat #HT15-1KT, Sigma Aldrich) for collagen
accumulation was performed on the heart, aorta and kidney sections according to
manufacturer’s instructions with some modifications. Briefly, slides were prefixed in
10% formalin for 20 min followed by fixation in Bouin’s reagent overnight at room
temperature. Next day, slides were washed in running tap water to drain the yellow stain
from Bouin’s reagent completely followed by washing in ddw. Weigert’s iron
hematoxylin solution (Cat# HT1079, Sigma Aldrich) was prepared according to vendor’s
instructions and applied on the sections for 5 min, and excess stain was removed by
rinsing under tap water followed by rinsing with ddw. Slides were then incubated with
scarlet-fuschin for 5 min, then washed again with tap water followed by washing in ddw.
1:1:2 volume of phosphotungstic acid, phosphomolybdic acid, and ddw was applied on
the slide for 10 min. The solution from the slides was drained on a paper towel and then
incubated with analine blue for 7 min, then washed with ddw. Tissue sections were then
differentiated in 1% glacial acetic acid for 30 sec and then washed twice in ddw followed
by dehydration in increasing strengths of alcohol and clearing in xylene after which slides
were mounted using permount.
3.6

Measurement of Oxidative Stress

3.6.1 Measurement of NADPH Oxidase Activity
NADPH oxidase activity was determined in heart homogenates by measuring
lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate)-enhanced chemiluminescence, as
described previously,219 with some modifications. Following anesthesia, a transcardial
PBS perfusion was performed; hearts and kidneys were harvested and snap-frozen in
liquid N2 and stored at -80°C until use. Tissues were homogenized and sonicated in lysis
buffer containing protease inhibitors (20 mmol/L phosphate buffer, 1 mmol/L EGTA, 10
μg/ml aprotinin, 0.5 μg/ml leupeptin, 0.7 μg/ml pepstatin, 0.5 mmol/L
phenylmethylsulphonylfluoride, and 150 mmol/L sucrose). Samples were then
centrifuged at 3,000 g for 10 min at 4°C, and supernatants were kept on ice until use.
Protein content in the samples was determined by the Bradford method, and equal
amounts of protein were combined 1:1 with a reaction mixture containing 5 μmol/L
lucigenin (final concentration) and 100 μmol/L NADPH (final concentration).
Luminescence was measured every minute for 10 min with a luminometer (Turner
Designs, Sunny Vale, CA; model TD-20/20). Lysis buffer was used as a blank and
subtracted from each reading and activity expressed as arbitrary units.
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3.6.2 Measurement of Urinary TBARS
Levels of TBARS, byproduct of lipid peroxidation in the urine were measured
using TBARS assay kit (Cayman cat # 10009055) as per manufacturer’s instructions.
3.6.3 Measurement of ROS Production
To measure ROS productions, sections of thoracic aortae, hearts and kidneys were
exposed to DHE (Cat #D-2310, Life Technologies, NY) following the previously
described and validated method.220 Aortic sections were incubated in PBS for 30 min at
37°C and then encircled with a hydrophobic pen. DHE (2 μM for aorta, 5 μM for heart
and kidney) was topically applied. Sections were further incubated at 37°C in a lightprotected humidified chamber for 30 min. Sections were then rinsed in PBS, and
fluorescence was detected with a 585-nm filter and an Olympus® inverted system
microscope (Olympus America, Inc.; model DP71). Superoxide production, was
measured as fluorescence intensity of 2-Hydoxyethiduim (OHE). Images were
photographed with an Olympus® digital camera (Olympus America, Inc., model DP71)
and analyzed using ImageJ 1.42 (http://rsb.info.nih.gov/nih-image; National Institutes of
Health).
3.7

Analysis of Vascular Function

3.7.1 Vascular Reactivity
Following anesthesia, the thoracic aortas were quickly dissected free and cleaned
of surrounding tissue, and approximately 2-mm rings were mounted in a wire myograph
system (Danish Myo Technology, Aarhus, Denmark; model 610M) as previously
described.14 Vessels were continuously bathed in Krebs buffer (composition in mmol/L:
118 NaCl, 4.7 KCl, 25 NaHCO3, 1.2 MgSO4, 1.2 KH2PO4, 11.1 glucose, 2.5
CaCl2.2H2O) at 37°C, which was gassed with 95% O2 and 5% CO2 to maintain pH 7.4.
An initial tension of 9 mN was placed on the vessels and allowed to equilibrate for
approximately 30 min. To confirm the viability of the vessels, they were initially tested
for constriction to 60 mM KCl and then washed three times with fresh Krebs buffer.
Cumulative concentration response curves to phenylephrine (PE) and ET-1 were obtained
and responses measured as force of contraction (mN).
3.7.2

Endothelium-Dependent and Independent Vasodilation

Endothelial function was examined14 by constricting the vessels with the
concentration of PE that evoked a maximal response followed by adding increasing
concentrations of acetylcholine (ACh). Changes in the response of vessels to ACh were
measured and presented as a percentage of the PE-induced constriction. Endothelium-
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independent vasodilation was studied by constricting the vessels with the concentration
of PE that evoked a maximal response followed by adding increasing concentrations of
sodium nitroprusside (SNP). Changes in the response of vessels to SNP were measured
and presented as a percentage of the PE-induced constriction.
3.8

Assessment of Vascular Remodelling

Aortic sections were stained with hematoxylin and eosin and viewed using an
Olympus® inverted system microscope (Olympus America, Inc., Melville, NY; model
IX50) and photographed with an Olympus® digital camera (Olympus America,Inc.;
model DP71). Images were analyzed using ImageJ 1.42 (http://rsb.info.nih.gov/nihimage; National Institutes of Health).
3.9

Western Blot Analysis

Heart and kidney samples were homogenized in lysis buffer, and protein content
was determined by the Bradford method. 50 μg of proteins were loaded and resolved on
8% or 12% SDS-polyacrylamide gels and processed for western blot analysis as
described.221 Blots were probed with different primary and corresponding secondary
antibodies (Table 3.1) Intensity of the bands was measured with ImageJ 1.42 software.
3.10

Real-Time PCR Analysis

Total RNA was extracted from the hearts with TRIzol reagent (Invitrogen, Grand
Islands, NY) according to the manufacturer’s protocol. 1μg of purified RNA was reverse
transcribed using SuperScriptTM III First Strand synthesis system (Invitrogen).
Transcription level was normalized to cyclophilin D. Primers were designed (Table 3.2).
The values were calculated by 2-ΔΔCt method.222

3.11

Analysis of Renal Function

Mice were individually housed in tecniplast metabolic cages. They were allowed
to acclimate to the cages for 24 hrs on day 11 of the experiment. On day 13, urine was
collected and its volume was measured along with food and water intake. Renal function
including urine output, osmolality using a Vapro® vapor pressure osmometer (Wescor,
South Logan, UT; model 5520), protein content by the standard Bradford method was
determined as described previously. Serum ET was measured at our endocrinology core
unit using an ELISA assay.
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Table 3.2.
Genes

List of primer sequences
Forward Sequence

Reverse Sequence

cPLA2α

GGG CCA TGG TGG GAT TC

TAC CAT GTG GAT CCA GAA AGA C

CPLA2β

CCT GAG TAC CTT TGA CTT TGG G

CTT TGT CAG GAG GTC AGT GAA G

CPLA2γ

GGA TCC TTT GCA CTA CTT GGA G

GTT GTG CTC TAG CTT TAG GGT C

sPLA2α
PLC-β1
PLC-β2
PLC-β3
PLC-β4
PLD1
PLD2

CAA AGG GAA GAA GCC CAA ATG
GGA GGT GGT TCA GTA CAT CAA G
ATA GCC TCT CCT GTT ATC CTC C
GAG AGG ATG AGG AGG AAG ATG AAG
GGA CAA GTG CTA GAA TGT TCC C
GGA AAG GAA TAT CAG GCT GGT C
CCT CCA GAG ACA CAA AGT CTT G

AGG AAG TTG GAT GCC AAG AG
CCT GGG TTC TCT CTT TCT ATC TCC
CTT GTA CAC GGA TTC TGG GAA G
GAA GAG CTG AGG CAT GTA GTT G
GTT CTA GTG ATA CTC CTC ACT GGG
GAA ATA GAG AGG GAA CTG CAC C
CAC CTC TTG GAC CAT CGA TAA C

p58IPK
Xbp1
CHOP
GRP78

TGG AGT AAA TGC GGA TGT GG
AAG AAA GCC CGG ATG AGC
TGT TGA AGA TGA GCG GGT G
AGT TGA TAT TGG AGG TGG GC

ACG GTC GCT CTC CTA TAG TAT G
AGC GTG TTC TTA ACT CCT GG
AGG TTC TGC TTT CAG GTG TG
CAT TGA AGT AAG CTG GTA CAG TAA C
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3.12

Urinary Levels of PGE2 Metabolite

PGE2 is rapidly converted in vivo to its 13,14-dihydro-15-keto metabolite that
further under goes degradation to PGA products, thus we measured the concentration of
PGE2 metabolites (PGEM) using an Prostaglandin E Metabolite EIA ELISA kit (Cayman
Cat# 514531) as per manufacturer’s instructions.

3.13

Assessment of GFR

Plasma and urine creatinine levels were determined at the national mouse
metabolic phenotyping center at Yale University. Creatinine clearance as a measure of
GFR was calculated using the below formula and expressed as ul/min.
Creatinine clearance = Urine Creatinine x Urine Volume
Plasma Creatinine x 24 x 60
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CHAPTER 4.
4.1

RESULTS

Aim 1. To Determine the Contribution of cPLA2α to Ang II-Induced
Hypertension and Associated Cardiovascular Pathophysiology

4.1.1 cPLA2α Gene Disruption Does Not Alter Expression of Other Phospholipase
Enzymes
To asses if cPLA2α gene disruption alters the expression of other related genes in
the phospholipase family; mRNA expression of various phospholipase enzymes was
determined by quantitative Real-time PCR. Total RNA was extracted from the hearts of
both cPLA2α+/+ and cPLA2α-/- mice as described in the methods. mRNA expression of
cPLA2α was absent but not of PLA2, PLC, PLD in the cardiac tissue of cPLA2α-/- mice.
(Figure 4.1A)
PL-Cβ2, D1, D2 have been implicated in cardiovascular diseases. To asses if Ang
II infusion and/or cPLA2α gene disruption altered their protein expression, western blot
analysis was performed. cPLA2α gene disruption did not alter protein expression of these
enzymes in the hearts of cPLA2α-/- mice. (Figure 4.1B)
4.1.2 cPLA2α Contributes to the Development of Ang II-Induced Hypertension,
Activation of Cardiac cPLA2 and Increased Excretion of PGE2 Metabolites
Ang II infusion over a period of 13 days significantly increased SBP, measured by
the tail cuff method (Figure 4.2A) and radio telemetry (Figure 4.2B) in cPLA2α+/+ but
not cPLA2α-/- mice. cPLA2 activity measured by its phosphorylation, but not its protein
expression, was significantly increased in the cardiac tissue of Ang II-infused cPLA2α+/+
mice; the expression of cPLA2 protein was absent in cPLA2α-/- mice. (Figure 4.2C, D)
This increase in SBP and activity of cPLA2 correlated with increased urinary excretion of
PGE2 metabolites in cPLA2α+/+ but not cPLA2α-/- mice. (Figure 4.2E)
4.1.3

Inhibition of Arachidonic Acid Metabolism, Abrogated Ang II-Induced
Hypertension in cPLA2α+/+ Mice

In order to confirm our hypothesis that AA metabolism via cPLA2α is crucial in
development of hypertension, ETYA, a competitive inhibitor of AA metabolism was
used. In a separate series of experiments, BP was recorded in 4 groups of cPLA2α+/+mice.
Mice were infused with vehicle-saline, Ang II, vehicle-ETYA (i.p) and Ang II+ETYA for
a period of 13 days. BP was recorded once every week. Ang II increased SBP and
treatment with ETYA every third day abrogated Ang II-induced hypertension (Figure
4.3).
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Figure 4.1
cPLA2α gene disruption prevents expression of cPLA2α but not other
related phospholipase enzymes
Comparison of myocardial mRNA expression levels of various phospholipases between
cPLA2α+/+ and cPLA2α−/− mice at baseline (A). Comparison of protein expression in the
heart from both vehicle and Ang II-treated cPLA2α+/+ and cPLA2α−/− mice (B).
*P< 0.05 cPLA2α+/+ vs. cPLA2α-/- (n = 4 for all experiments, and data are expressed as
mean ± SEM)
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ł

Figure 4.2
cPLA2α contributes to the development of Ang II-induced
hypertension, activation of cardiac cPLA2α and increased excretion of PGE2
metabolites
SBP measured by tail cuff (A) and radiotelemetry (B). cPLA2 activity measured by its
phosphorylation by western blot analysis (C) in the cardiac tissue. Quantified data (D)
PGE2 metabolite excretion in urine (D)*P< 0.05 cPLA2α+/+ Veh vs. cPLA2α+/+ Ang II,
łP< 0.05 cPLA2α+/+ Veh vs. cPLA2α-/- Veh #P< 0.05 cPLA2α+/+ Ang II vs. cPLA2α-/- Ang
II (n = 3-6) for all experiments, and data are expressed as mean ± SEM)
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Figure 4.3
Inhibition of arachidonic acid metabolism, abrogated Ang II-induced
hypertension in cPLA2α+/+ mice
*P< 0.05 vehicle vs. Ang II, #P< 0.05 Ang II vs. Ang II+ETYA. (n = 6 for all
experiments; data are expressed as mean ± SEM).
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4.1.4 cPLA2α Gene Disruption Attenuates Cardiac Dysfunction and Hypertrophy
Associated with Ang II-Induced Hypertension
Cardiac functional and structural changes were measured by echocardiography on
the 12th day of infusion of Ang II or its vehicle. M-mode images of the left ventricle (LV)
in the parasternal long-axis view demonstrated dilated cardiomyopathy as indicated by
LV chamber enlargement and impaired contractility in Ang II-infused cPLA2α+/+ but not
cPLA2α-/- mice (Figure 4.4). Various parameters, measured, (Table 4.1), revealed
cardiac dysfunction including an increase in LV mass in Ang II-infused cPLA2α+/+ but
not cPLA2α-/- mice.
4.1.5 cPLA2α Gene Disruption Prevents Cardiac Interstitial Fibrosis
It is well established that hypertension, in both humans and animal models results
in fibrosis in the cardiac, vascular and renal tissues. To determine the contribution of
cPLA2α in Ang II-induced cardiac interstitial fibrosis, immunohistochemical analysis was
performed on cardiac sections for α-smooth muscle actin and TGF-β. Masson’s trichrome
staining was also performed on the heart sections to assess collagen accumulation. The
heart sections of Ang II-infused cPLA2α+/+ but not cPLA2α-/- mice showed fibrosis as
indicated by increased staining with intracardiac α-smooth muscle actin (Figure 4.5A),
transforming growth factor (TGF)-β (Figure 4.5B), and collagen (Figure 4.5C).
4.1.6 cPLA2α Gene Disruption Prevents Cardiac Inflammation
Recent studies have demonstrated the role of immune system activation in various
models of hypertension. To determine the contribution of cPLA2α to inflammation
associated with Ang II-induced hypertension, immunohistochemistry was performed for
F4/80+ macrophages, and CD3+ T-lymphocytes in the cardiac tissue of cPLA2α +/+ and
cPLA2α-/- mice. Ang II caused infiltration of F4/80+ macrophages (Figure 4.6A) and
CD3+ T cells (Figure 4.6B) in the hearts of cPLA2α+/+ but not cPLA2α-/- mice.
4.1.7 cPLA2α Gene Disruption Protects Against Ang II-Induced Vascular
Remodeling
To assess vascular remodeling, aortas were stained with Hematoxylin and Eosin
(Figure 4.7A) and media:lumen ratio was calculated (Figure 4.7B). The aortae were also
stained for α-smooth muscle actin and collagen. Ang II increased media:lumen ratio
(Figure 4.7B), α-smooth muscle actin muscle actin (Figure 4.7C, D) positive stained
cells and collagen accumulation (Figure 4.7E, F) in aortas of cPLA2α+/+ mice compared
to cPLA2α-/- mice.
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Figure 4.4
cPLA2α gene disruption attenuates cardiac dysfunction and
hypertrophy associated with Ang II-induced hypertension
Echocardiograms of the left Ventricle obtained in M mode parasternal long axis view.
Red dotted line indicates LVIDs and green dotted line indicates LVIDd.
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Table 4.1.

Parameters
EF%
FS%
SV
CO
LV mass
LVID-d
LVID-s
LVAW-s
LVAW-d
LVPW-s
LVPW-d
EDV
ESV
IVS-s
IVS-d

Paramaters of cardiac function
cPLA2α+/+
Vehicle
Ang II
63.94 ± 1.0
40.66 ± 3.2*
34.19 ± 0.8
19.39 ± 1.9*
39.78 ± 1.2
23.48 ± 1.6*
16.35 ± 0.6
11.80 ± 1.1*
83.07 ± 7.3 146.66 ± 6.2*
3.61 ± 0.2
4.31 ± 0.05*
2.33 ± 0.1
3.63 ± 0.1*
1.24 ± 0.1
1.44 ± 0.2
1.10 ± 0.1
1.36 ± 0.1
0.95 ± 0.1
1.15 ± 0.01
0.68 ± 0.03
1.05 ± 0.04
62.36 ± 1.8
75.78 ± 1.9*
21.39 ± 0.7
53.50 ± 3.5*
1.48 ± 0.02
1.44 ± 0.01
0.98 ± 0.04
1.06 ± 0.02

cPLA2α-/Vehicle
Ang II
63.47 ± 2.4
63.97 ± 1.3#
33.77 ± 1.7
34.17 ± 0.9#
37.33 ± 2.8
36.60 ± 2.5#
15.11 ± 0.7
16.84 ± 2.5#
92.90 ± 2.9
107.56 ± 7.8#
3.60 ± 0.2
3.66 ± 0.1#
2.33 ± 0.2
2.37 ± 0.1#
1.31 ± 0.1
1.55 ± 0.1
0.97 ± 0.1
1.07 ± 0.1
1.22 ± 0.2
1.56 ± 0.1
0.85 ± 0.1
0.91 ± 0.04
57.63 ± 4.7
58.59 ± 4.3#
22.38 ± 2.9
21.97 ± 2.5#
1.21 ± 0.1
1.65 ± 0.1
0.86 ± 0.1
1.05 ± 0.1

EF, ejection fraction; FS, fractional shortening; SV, stroke volume (ul); CO, cardiac
output (ml/min); LV mass, left ventricular mass (mgs); LVID, LV internal dimension
(mm); LVAW, LV anterior wall (mm); LVPW, LV posterior wall (mm); EDV, end
diastolic volume (ul); ESV, End systolic volume; IVS, Intraventricular septum (mm). s, d
indicate systole or diastole.
The parameters listed in the table were measured using M-mode and B-mode images in
the short and parasternal long-axis views as described in the methods.
*P< 0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P< 0.05 cPLA2α+/+Ang II vs.
cPLA2α-/- Ang II (n=4-6 for each group; data are expressed as mean ± SEM).
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Figure 4.5

cPLA2α gene disruption prevents cardiac interstitial fibrosis

Immunohistochemical staining of α-smooth muscle actin (A) and TGF-β (B), (indicators
of interstitial fibrosis). Masson’s trichrome staining for collagen accumulation (intense
blue staining) (C) (n=4 for each group)
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Figure 4.6

cPLA2α gene disruption prevents cardiac inflammation

Immunohistochemical analysis for F4/80+ macrophages (A) and CD3+ T cells (B) in
cardiac sections (n=4 for each group)
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Figure 4.7
remodeling

cPLA2α gene disruption protects against Ang II-induced vascular

Sections of aortae were stained with hematoxylin and eosin (A), α-smooth muscle actin
(C), and Masson’s trichrome for collagen (E). (B,D,F represent corresponding
quantification of data)
*P< 0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P< 0.05 cPLA2α+/+Ang II vs.
cPLA2α-/-Ang II (n=3-5 for each group; data are expressed as mean ± SEM).
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4.1.8 cPLA2α Gene Disruption Prevents Increased Vascular Reactivity and
Endothelial Dysfunction in Ang II-Induced Hypertension
Ang II-induced hypertension was associated with increased response of aorta to
vasoconstrictors phenylephrine (Figure 4.8A) and endothelin-1 (Figure 4.8B) in
cPLA2α+/+ mice; these increases were abrogated in cPLA2α-/- mice. Ang II-infusion
caused endothelial dysfunction, as indicated by diminished dilation to ACh in aorta
preconstricted with phenylephrine in cPLA2α+/+ but not cPLA2α-/- mice (Figure 4.8C).
The endothelial-independent relaxation of aorta to SNP, that acts directly on vascular
smooth muscle was not altered (Figure 4.8D).
4.1.9 cPLA2α Gene Disruption Does Not Alter Expression of AT1, AT2, MAS
Receptors and ACE
To determine if decreased BP during Ang II-infusion in cPLA2α-/- mice is a result
of alterations in expression of AT1, AT2, Ang (1-7) Mas receptor, or ACE, western blot
analysis was performed to determine their protein expression in the cardiac tissue.
Expression of AT1, AT2, Mas receptor, and ACE were not altered in any treatment
groups (Figure 4.9).
4.1.10 cPLA2α Gene Disruption Protects Against Ang II-Induced Cardiovascular
Oxidative Stress
Oxidative stress has been implicated in various models of hypertension including
, and Ang II-induced activation of cardiac NADPH oxidase depends on PLA2
Ang II
activity in vascular smooth muscle cells in vitro.223,224 Therefore, we investigated whether
cPLA2 gene disruption prevents Ang II-induced oxidative stress in heart and aorta.
NADPH oxidase activity measured by lucigenin-based luminescence assay was increased
in the hearts of Ang II-infused cPLA2α+/+ but not cPLA2α-/- mice (Figure 4.10A).
Infusion of Ang II increased cardiac (Figure 4.10B, C) and aortic (Figure 4.10D, E)
ROS production in cPLA2α+/+ but not in cPLA2α-/- mice measured by fluorescence of 2hydroxyethidium generated after exposure to DHE.
16,166

4.1.11 cPLA2α Gene Disruption Prevents Endoplasmic Reticulum Stress in Ang IIInduced Hypertension
Endoplasmic reticulum (ER) stress has been implicated in Ang II-induced
hypertension.225 To determine if Ang II-infusion promotes ER stress in the heart and if it
is dependent on cPLA2α, we measured mRNA expression of ER stress biomarkers
p58IPK, GRP78, XBP and CHOP. Ang II infusion increased cardiac mRNA expression of
p58IPK that is induced in the early adaptive phase of the unfolded protein response, and
CHOP (GADD153), a chronic ER stress marker226 in cPLA2α+/+ but not in cPLA2α-/- mice
(Figure 4.11).
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Figure 4.8
cPLA2α gene disruption prevents increased vascular reactivity and
endothelial dysfunction in Ang II-induced hypertension
The vascular response of aorta to increasing concentrations of PE (A) ET-1 (B) The
vascular response to increasing concentrations of Ach (endothelium-dependent relaxation
(C) and SNP (endothelium-independent relaxation) (D) was examined in the thoracic
aorta from animals in each of the groups.
*P< 0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P< 0.05 cPLA2α+/+Ang II vs.
cPLA2α-/- Ang II (n = 5 for all experiments; data are expressed as mean ± SEM).
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Figure 4.9
cPLA2α gene disruption does not alter expression of AT1, AT2, MAS
receptors and ACE
Western blot analysis was performed on the heart homogenates with respective
antibodies. Protein expression of these receptors and ACE was not altered (n = 3 for all
experiments)
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Figure 4.10 cPLA2α gene disruption protects against Ang II-induced
cardiovascular oxidative stress
NADPH oxidase activity measured in kidney homogenate (A), ROS production
determined by DHE staining in the heart (B,C) and aorta (D,E)quantified as fluorescence
of 2-OHE
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/Ang II (n=5 for each group; data are expressed as mean ± SEM).
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Figure 4.11 cPLA2α gene disruption prevents ER stress in Ang II-induced
hypertension
RT-PCR analysis was performed using cardiac mRNA for various ER stress biomarkers:
p58IPK, GRP78, XBP, and CHOP.
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/Ang II (n = 4 for all experiments; data are expressed as mean ± SEM).
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4.1.12 cPLA2α Gene Disruption Prevents Ang II-Induced Phosphorylation of
ERK1/2 and c-Src
It is well established that, in VSMC, Ang II increases the production of ROS, and
activity of ERK1/2 and cSrc that contributes to hypertrophy.59 ERK1/2 also promotes
phosphorylation of cPLA2.3 Ang II-infusion increased ERK1/2 (Figure 4.12A) and cSrc
activity (Figure 4.12B) as measured by phosphorylation of these kinases in the heart
tissue of cPLA2α+/+ but not in cPLA2α-/- mice.
4.2

Aim 2. To Demonstrate that cPLA2α Is Essential in Ang II-Induced Renal
Pathophysiology Associated with Hypertension

4.2.1 cPLA2α Gene Disruption Prevents Against Ang II-Induced Altered Renal
Hemodynamics
Renal Doppler imaging was performed and renal artery resistive (Figure 4.13D)
and pulsatility index (Figure 4.13E) were calculated as a measure of resistance and
variability of blood velocity in the renal artery. These parameters are widely used to
assess renal failure and extent of damage in humans. In the present study, Ang II infusion
for 13 days increased renal vascular resistance and pulsatility index in cPLA2α+/+ but not
in in cPLA2α-/- mice.
4.2.2 cPLA2α Gene Disruption Prevents Ang II–Induced Renal Dysfunction
Water intake and urine output were not different between cPLA2α+/+ and cPLA2α-/mice. Infusion of Ang II for 13 days increased water intake (Figure 4.14A), urine output,
(Figure 4.14B), decreased urine osmolality (Figure 4.14C), increased glomerular
filtration rate as determined from creatinine clearance (Figure 4.14D), and caused
proteinuria (Figure 4.14E) in cPLA2α+/+ but not cPLA2α-/- mice.
4.2.3 cPLA2α Gene Disruption Prevents Renal Fibrosis in the Kidney
Increased interstitial staining of α-SMA (Figure 4.15A) and TGF-β (Figure
4.15B) indicators of interstitial fibrosis, was observed in renal sections from Ang IIinfused cPLA2α+/+ but not in cPLA2α-/- mice. Masson’s trichrome staining revealed
increased collagen accumulation (intense blue staining) (Figure 4.15C) in the interstitial
space in Ang II-infused cPLA2α+/+ but not cPLA2α-/- mice.
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Figure 4.12 cPLA2α gene disruption prevents Ang II-induced phosphorylation of
ERK1/2 and cSrc
Erk1/2 (A) and cSrc (B) activities were measured in heart homogenates by Western blot
analysis as described in the methods (n = 3 for all experiments).
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/Ang II
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Figure 4.13 cPLA2α gene disruption prevents against Ang II-induced altered renal
hemodynamics
Representative ultrasound B mode image of the kidney in transverse view (A) Color
Doppler to visualize blood flow (B) Pulse wave Doppler mode (C) Renal artery resistive
index (D) and renal artery pulsitality index (E)
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/Ang II (n = 4 for all experiments; data are expressed as mean ± SEM)

48

Figure 4.14

cPLA2α gene disruption prevents Ang II–induced renal dysfunction

Water intake (A), urine output (B) measured on day 13 of Ang II infusion, urine
osmolality (C), creatinine clearance (D) and protein excretion in the urine (E) was
measured
*P<0.05 cPLA2α+/+ vehicle vs. cPLA2α+/+Ang II, #P<0.05 cPLA2α+/+Ang II vs. cPLA2α-/(n = 6-10 for all experiments; data are expressed as mean ± SEM)
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Figure 4.15

cPLA2α gene disruption prevents renal fibrosis in the kidney

Immunohistochemical analysis for α-SMA (A), TGF-β (B) and Masson’s trichrome
staining for collagen (C) in renal sections.
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4.2.4 cPLA2α Gene Disruption Prevents Renal Inflammation
To determine the contribution of cPLA2α to inflammation associated with Ang IIinduced end organ damage, we examined the localization of CD3+ T-lymphocytes and
F4/80+ macrophages in the renal tissue. Ang II infusion resulted in increased
accumulation of CD3+ T cells in the interstitium (Figure 4.16A) and glomerulus (Figure
4.16B) and infiltration of F4/80+ macrophages (Figure 4.16C) in the renal interstitium of
cPLA2α +/+ but not cPLA2α-/- mice
4.2.5 cPLA2α Gene Disruption Protects Against Ang II-Induced Renal Oxidative
Stress
Infusion of Ang II for 13 days increased renal NADPH oxidase activity (Figure
4.17A) and urinary TBARS (Figure 4.17B), a byproduct of lipid peroxidation in
cPLA2α+/+ but not in cPLA2α-/- mice. This data correlated with increased superoxide
production in renal sections of cPLA2α+/+ mice, as indicated by 2-OHE fluorescence
intensity (Figure 4.17C, D). This increase was not observed in cPLA2α-/- mice infused
with Ang II
4.2.6

Protection Against Ang II-Induced Hypertension in cPLA2α-/- Mice Is
Independent of Endothelin

Ang II infusion increased endothelin levels (Figure 4.18) to the same extent in
both cPLA2α+/+ and cPLA2α-/- mice, however this did not reach significant difference
demonstrating that reduced SBP in cPLA2α-/- mice after Ang II infusion is independent of
endothelin.
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Figure 4.16

cPLA2α gene disruption prevents renal inflammation

CD3+ T cell staining in the interstitium (A) and glomerulus (B) and F4/80+ macrophages
in the interstitium (C) of the kidney.
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Figure 4.17 cPLA2α gene disruption protects against Ang II-induced renal
oxidative stress
NADPH oxidase activity measured in kidney homogenate (A), urinary TBARS (B), ROS
production determined by DHE staining (C) quantified as fluorescence of 2-OHE (D) (n
= 5-6 for all experiments; data are expressed as mean ± SEM)
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Figure 4.18 Protection against Ang II-induced hypertension in cPLA2α-/- mice is
independent of endothelin
Endothelin levels measure by HPLC (n = 6 for all experiments; data are expressed as
mean ± SEM)
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CHAPTER 5.
5.1

DISCUSSION

Aim 1. To Determine the Contribution of cPLA2α to Ang II-Induced
Hypertension and Associated Cardiovascular Pathophysiology

The novel finding of this study is the demonstration that cPLA2α is crucial for the
development of Ang II-induced hypertension and associated cardiovascular dysfunction,
hypertrophy, cardiac fibrosis, inflammation, oxidative stress, and activation of ERK1/2
and cSrc in mice. This conclusion is based on my finding that infusion of Ang II
increased SBP in cPLA2α+/+ mice and this was minimized by cPLA2α gene disruption.
The selectivity of this effect of cPLA2α gene disruption in our mice was indicated by loss
of cardiac expression of its mRNA but not that of other related PL enzymes: sPLA2α,
cPLA2E, and cPLA2J; PLCE1, 2, 3, and 4; and PLD1 and PLD2. The protein expression
of PLA2 but not PLCβ2, PLD1, or PLD2 was also absent in cPLA2α-/- mice. Since
cPLA2α selectively catalyzes release of AA from tissue lipids227 and Ang II is known to
activate cPLA2 to release AA, cPLA2 appears to mediate the hypertensive effect of Ang
II via AA release. Supporting this view was our finding that cPLA2 activity, as indicated
by its phosphorylation, was increased in the heart of cPLA2α+/+ but not cPLA2α-/- mice.
The induction of eicosanoid production by lipopolysaccharide and calcium ionophore
A23187 in peritoneal macrophages and furosemide-induced PGE2 excretion was also
abolished in cPLA2α-/- mice.204,228,229 . In the present study, Ang II infusion increased the
urinary output of PGEM. Moreover, administration of inhibitor of AA metabolism,
ETYA, blocked Ang II-induced increase in SBP in cPLA2α+/+ mice. Therefore, it appears
that metabolites of AA with pro-hypertensive effects contribute to the development of
hypertension caused by this peptide in these mice. Since cPLA2α gene disruption or
ETYA did not alter basal BP, it appears that cPLA2α activation and release of AA and its
metabolites are not required to maintain basal BP.
The increase in BP produced by Ang II in cPLA2α+/+ mice was associated with
cardiac dysfunction as indicated by decreased EF, FS, CO and increased EDV and ESV,
cardiac hypertrophy as shown by increased LV mass. These events were minimized in
cPLA2α-/- mice, suggesting an essential role of cPLA2α+/+ in cardiac dysfunction and
hypertrophy. Moreover, in the present study, cardiac fibrosis and inflammation as
indicated by increased intracardiac staining of D-SMA myofibroblasts, TGF-E, as well as
by increased infiltration of F4/80+ macrophages and CD3+ T cells in Ang II-infused
cPLA2α+/+ mice were prevented in cPLA2α-/- mice. These findings suggest that
cPLA2α/AA also mediate cardiac fibrosis and inflammation associated with Ang IIinduced hypertension. cPLA2α was also found to be critical for increased vascular
remodeling and reactivity associated with Ang II-induced hypertension characterized by
an increase in various parameters such as media:lumen ratio, D-SMA, deposition of
collagen, as well as by increased contractile response of aorta to PE and ET-1 in
cPLA2α+/+ but not cPLA2α-/- mice. Although the effect of Ang II on cardiovascular
remodeling has been shown to be independent of an increase in BP,230-233 we cannot
exclude the possibility that the protection against Ang II-induced cardiovascular
remodeling in cPLA2α-/- mice could also be due to decreased BP. The precise mechanism
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by which increase in BP causes cardiovascular remodeling is not known. Since stretch
can increase cPLA2 activity and eicosanoid production234 and 20-HETE contributes to
pressure-induced myogenic tone,235 it raises the possibility that the increased stretch
associated with hypertension might also result in cPLA2α activation and generation of
eicosanoids that contribute to Ang II-induced cardiovascular remodeling. Ang II-induced
hypertension is also known to be associated with endothelial dysfunction.16 Our finding
that Ang II-induced endothelial dysfunction, as indicated by diminished relaxation of
aorta to ACh but not to SNP, an agent that acts directly on VSMCs, occurs selectively in
cPLA2α+/+ but not cPLA2α-/- mice, suggests that cPLA2α is essential for endothelial
dysfunction associated with Ang II-induced hypertension. Moreover, endothelial
dysfunction in larger vessels is dependent on NO.236 Hypertension caused by the inhibitor
of NO synthesis, L-NG-nitroarginine methyl ester, which has been attributed to increased
activity of RAS and sympathetic nervous system,237,238 is also associated with endothelial
dysfunction in the aorta. Both hypertension and endothelial dysfunction are prevented in
cPLA2α-/- mice.9
The mechanism by which cPLA2α gene disruption protects against Ang IIinduced hypertension and cardiovascular remodeling, inflammation, increased vascular
reactivity, and endothelial dysfunction could be due to alterations in expression of Ang II,
Ang (1-7) receptors, and ACE enzyme. However, this possibility appears to be unlikely
because the level of expression of AT1, AT2, Mas receptor and ACE enzyme examined
in the heart were not different in cPLA2α-/- compared to cPLA2α+/+ mice. Oxidative stress
and activation of immune system have been implicated in various models of hypertension
including Ang II-induced hypertension.239,240 In the present study, Ang II-induced
hypertension was associated with increased oxidative stress, as shown by increased
cardiac NADPH oxidase activity, ROS production in the heart and aorta, and cardiac
infiltration of F4/80+ macrophages and CD3+ T lymphocytes in cPLA2α+/+ mice. These
changes were prevented in cPLA2α-/- mice, suggesting that increased oxidative stress and
inflammation in Ang II-induced hypertension are dependent on cPLA2α. Supporting this
view, it has been shown that Ang II increases NADPH oxidase activity by activating
cPLA2 and release of AA in VSMCs.223,224 cPLA2α generated AA has also been
implicated in NADPH oxidase activation in human monocytes and myeloid cell line
PLB-985.241,242 AA metabolites generated by COX, PGE2 via its actions on EP1 and EP3
receptors243,244 and TXA2245 contributes to Ang II-induced hypertension. AA metabolites
formed by 12/15 LOX127,246 and by CYP450 4A (20-HETE),247,248 also contribute to Ang
II-induced hypertension. Therefore, protection against Ang II-induced hypertension and
associated cardiovascular pathogenesis in cPLA2α-/- mice is most likely due to lack of AA
release and generation of one or more metabolites that mediate hypertensive effects of
Ang II. Supporting this conclusion was our finding that Ang II infusion increased the
urinary excretion of PGEM in cPLA2α+/+ but not cPLA2α-/- mice.
The site of pro-hypertensive eicosanoids generated by cPLA2α that participate in
Ang II-induced hypertension is not known. Since cPLA2α is ubiquitously distributed in
various tissues and eicosanoids generated from AA act locally, it is possible that
eicosanoids generated at the site of action of Ang II including the cardiovascular, renal,
brain and cells of the immune system, could contribute to Ang II-induced hypertension.
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Recently, it has been shown that Ang II by stimulating expression of (pro)renin receptor
in the rat renal medulla through COX2-generated PGE2, via stimulation of EP4 receptors
increases renin release that partly contributes to Ang II-induced hypertension.249 Also
mice lacking macrophage 12/15 LOX have been shown to be resistant to L-NAME or
DOCA-salt induced hypertension.250 Ang II is known to cause hypertension by increasing
oxidative stress in subfornical organ (SFO) of circumventricular organs and via its
projections to PVN and from there to the brain stem, finally resulting in increased
sympathetic activity.251 cPLA2α is also present in the brain7,204 and
intracerebroventricular administration of PGE2 increases sympathetic nervous activity,
vasopressin release and BP.252 The demonstration that the effect of Ang II in increasing
BP is mediated by activation of the EP1 receptor by PGE2, formed by COX-1 and not
COX-2 in SFO, most likely by release of AA, suggests involvement of cPLA2.253
Therefore, it is possible that Ang II-induced hypertension in our study could be mediated
by activation of cPLA2α in the SFO as well as in the cardiovascular and renal systems.
Moreover, it has been reported that Ang II-salt hypertension, which is associated with
increased sympathetic activity and increased plasma levels of norepinephrine, are
minimized by inhibitor of COX-1, SC560 but not nemsulide, an inhibitor of COX 2
suggesting that COX-1 derived prostanoids by activating sympathetic nervous system
increase BP.254 The oxidative stress produced by Ang II in SFO is mediated by ER stress,
and inhibitors of ER stress minimize Ang II-induced hypertension.225 Activation of
cPLA2 is associated with increased ER stress.255 Inhibitors of ER stress reduce BP in
spontaneously hypertensive rats and the effect of endothelial-derived contractile factors,
by suppressing H2O2 production and expression of COX-1 and ERK1/2 and cPLA2
phosphorylation.256 However, our demonstration that cPLA2α gene disruption prevented
the cardiac expression of ER stress markers p58IPK and CHOP suggests that Ang II also
increases ER stress in the heart, but cPLA2α acts upstream of ER stress and NADPH
oxidase activity, most likely by generating AA/metabolites. The effect of vasoactive
agents, including Ang II, to promote influx of calcium and translocation of cPLA2α to the
nuclear envelope/ER,257 the site of AA metabolizing enzymes (COX, LOX, and CYP
P450),258-260 raises the possibility that cPLA2α via AA release and its metabolism by
these enzymes might regulate generation of ER stress and ROS production. In support of
this view, 12/15-LOX has been implicated in ER stress in adipocytes, pancreatic islets,
and rat liver.259
The increased ROS generated by Ang II promotes cardiovascular remodeling by
activating one or more signaling molecules.59 Our finding that Ang II-induced
hypertension was associated with increased cardiac ERK1/2 and cSrc activity in
cPLA2α+/+ but not in cPLA2α-/- mice suggests that these signaling molecules are most
likely activated by oxidative stress produced by cPLA2α-generated AA metabolites, thus
contributing to cardiovascular remodeling.
In conclusion, the present study provides the first evidence that the selective
release of AA by cPLA2α is crucial for the development of Ang II-induced hypertension
and associated cardiovascular pathophysiological changes including cardiovascular
remodeling, increased vascular reactivity, endothelial dysfunction, and cardiac
inflammation. These effects are most likely mediated by oxidative16,59,166 and ER
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stress225,256 generated by AA metabolism259 and predominantly by pro-hypertensive
eicosanoids resulting in activation of one or more signaling molecules including ERK1/2
and cSrc.
However, further studies using tissue specific knockout of cPLA2α and AA
metabolizing enzymes would allow assessment of their relative contribution in various
tissues to Ang II- and other models of hypertension and associated pathogenesis.
5.2

Aim 2. To Investigate if cPLA2α Is Essential for Renal Dysfunction and End
Organ Damage Associated with Ang II-Induced Hypertension

This study demonstrated that cPLA2D that selectively stimulates release of AA
from tissue lipids is indispensable for renal dysfunction, inflammation, and end organ
damage associated with Ang II-induced hypertension, most likely as a result of increased
production and/or action predominantly of pro-hypertensive eicosanoids and generation
of ROS. Eicosanoids generated from AA released by cPLA2, in various structures of the
kidney by their direct vascular, as well as tubular-glomerular actions, and, more
importantly by modulating and/or mediating the actions of various neurohumoral agents
contribute to renal anti- and pro-hypertensive mechanisms.126,127,243,244,261-265 This study
showed that the net effect of eicosanoids that contribute to renal pro-hypertensive
mechanism and associated renal dysfunction and end organ damage predominates over
those that participate in anti-hypertensive mechanisms in Ang II-induced hypertension.
Infusion of Ang II increased SBP in cPLA2D+/+, but not in cPLA2D-/-, mice. In the present
study, Ang II infusion also increased renal cPLA2 activity, as indicated by its
phosphorylation, without altering its expression in cPLA2D+/+, but not cPLA2D-/- mice.
This observation together with the demonstration that Ang II increases urinary output of
AA metabolites in cPLA2D+/+, but not cPLA2D-/- mice, and cPLA2D gene disruption also
inhibits the basal, as well as furosemide-induced, increase in urinary PGE2 excretion,229
suggest that eicosanoids generated by Ang II in the kidney are most likely due to AA
release consequent to activation of cPLA2D.
It has been shown that cPLA2 gene disruption does not alter renal function as
indicated by lack of changes in serum electrolyte or creatinine concentration, glomerular
filtration rate, and fractional Na+ or K+ excretion compared to cPLA2+/+ mice; however,
cPLA2 gene disruption produces concentration defect in older cPLA2-/- mice (>45
weeks).229 In the present study, cPLA2 gene disruption alone did not alter renal function
in 9 to 10 week old mice or cause any structural changes. However, in the present study
Ang II-induced increase in renal arterial resistance and pulsatility observed in cPLA2D+/+
mice was prevented in cPLA2D-/- mice. These observations suggest that one or more AA
metabolites predominantly with pro-hypertensive effects mediate the increase in renal
vascular resistance caused by Ang II in cPLA2+/+ mice. Supporting this view is the report
that inhibitor of AA metabolism ETYA acid attenuates Ang II-induced renal
vasoconstriction266 and the COX product, PGE2, via activation of EP1 and EP3 receptor,
and PGH2 and thromboxane A2 via thromboxane-prostanoid receptor, contributes to
pressor actions of Ang II.245 A recent study demonstrated Ang II-mediated activation of
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EP4 receptor via COX-2 derived PGE2 increases expression of (pro)renin receptor
locally in rat renal medulla and increases medullary and urinary activity of renin that
partly contributes to Ang II-induced hypertension.267 Products of AA generated via LOX
(12-HETE) and cytochrome P450 4A (20-HETE) also mediate Ang II-induced renal
vasoconstriction.248,268,269 In the present study, infusion of Ang II for 13 days in
cPLA2D+/+ mice also increased water intake, urine output, and glomerular filtration rate;
decreased urinary osmolality; and caused proteinuria in cPLA2D+/+ mice. Since all these
effects of Ang II were minimized in cPLA2D-/- mice, they are most likely mediated by
AA metabolites that contribute predominantly to pro-hypertensive mechanisms. The
cPLA2D-dependent dipsogenic effect of Ang II could be mediated by the central actions
of AA metabolite, Tx A2, because Tx A2 receptor blocker inhibits and Tx A2 receptor
activation enhances the effect of intracerebroventricularly administered Ang II.270 Ang II
stimulates the production of eicosanoids with both pro- and antihypertensive actions, and
the balance between their vascular, as well as tubular actions, most likely maintain renal
homeostasis.126,127,248,261-265,271 Therefore, it appears that renal dysfunction associated with
Ang II-induced hypertension is primarily due to loss of predominantly those eicosanoids
that contribute to pro- and not anti-hypertensive mechanisms. Since nonsteroidal antiinflammatory COX-2 inhibitors or COX gene disruption produce renal dysfunction and
hypertension in mice on a high salt diet due to loss of anti-hypertensive and renoprotective effect of PGI2,271 further studies in cPLA2D-/- mice on low and high salt diets
and other models of hypertension would allow assessment of the role of anti-hypertensive
eicosanoids including PGI2 and EETs in renal function.
cPLA2α is also present in immune cells, and AA released by its activation is
metabolized into eicosanoids with pro- and anti-inflammatory properties and is able to
generate cytokines/chemokines, which regulate both innate and adaptive immune
responses.272-277 In this study, infusion of Ang II for 13 days in cPLA2D+/+ mice caused
inflammation as demonstrated by increased renal infiltration of F4/80+ macrophages and
CD3+ T lymphocytes and damage as indicated by renal accumulation of D-smooth muscle
actin, TGFE, and collagen. Our findings that Ang II infusion failed to produce these
effects in cPLA2D-/- mice suggest that AA released by cPLA2D activation results in
production of predominantly pro-hypertensive eicosanoids that stimulate infiltration of
macrophages and CD3+ T lymphocytes in the kidney and promote production of
cytokines/chemokines and inflammation and renal fibrosis.
The effect of cPLA2D gene disruption to minimize Ang II-induced renal
dysfunction, renal damage, and inflammation without altering basal renal function
suggests that cPLA2α activity and hence the amount of AA released under basal
physiological conditions is low and does not appear to generate a sufficient amount of
eicosanoids to affect renal function. Supporting this view, it has been shown that,
although cPLA2 is constitutively active, it requires influx of extracellular calcium for its
translocation to the nuclear envelope and phosphorylation by one or more kinase for its
maximal activity to release AA.187,272 Several vasoactive agents that increase influx of
extracellular calcium, including Ang II, increase cPLA2 activity.10,11,278,279 In the present
study, Ang II increased cPLA2 activity in the kidney, as measured by its phosphorylation
and as shown from the elevated urinary excretion of AA metabolite PGEM in
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cPLA2D +/+, but not cPLA2D-/-, mice. Therefore, the increase in cPLA2 activity observed
in ischemia,204,280 diabetic nephropathy,281 glomerulonephritis,282 and polycystic kidney
disease283 is most likely due to associated increase in the activity of various vasoactive
systems including the renin-angiotensin system.284-287 Increased levels of Ang II would
result in increased calcium influx in various renal cell types, AA release, and generation
of eicosanoids that favor renal pro-hypertensive mechanisms and contribute to renal
dysfunction, inflammation, and end-organ damage.
The mechanism by which cPLA2D gene disruption minimizes Ang II-induced
renal dysfunction, inflammation, and end-organ damage could be the consequence of
decreased BP.288 The mechanical stretch and inflammation, which are associated with
hypertension, promote aortic stiffening via activation of p38 MAPK.289 The mechanical
stretch increases Ca2+ influx via stress-operated Ca2+ channels, which is known to
increase cPLA2 activity and generation of eicosanoids,234 and metabolites of AA increase
p38 MAPK activity.290 Therefore, it is possible that the effect of mechanical stretch
caused by high BP on cardiovascular remodeling, activation of immune cells, and endorgan damage might be mediated in part by pro-hypertensive eicosanoids. However, Ang
II also produces cardiovascular and renal pathophysiological changes independent of
increased BP.232,233 In transgenic rats carrying both human renin and angiotensinogen
genes, treatment with triple therapy (hydralazine, reserpine, and hydrochlorothiazide)
prevented increased BP but not end organ damage, inflammation, or cellular growth in
the kidney.233 Therefore, the protection against Ang II-induced renal dysfunction,
inflammation, and damage could also result from a pressure-independent mechanism. ET
has been implicated in Ang II-induced hypertension and some of its renal actions.267,291
However, in our study, ET was unlikely to mediate cPLA2D-dependent actions of Ang II
because it produced an equally insignificant increase in the plasma levels of ET in
cPLA2D-/- and cPLA2D +/+ mice.
Ang II is known to increase oxidative stress, activate immune cells that release
cytokines, and promote inflammation that have been implicated in the development of
hypertension and end organ damage.15,292,293 These finding that cPLA2D gene disruption
prevented Ang II-induced increase in NADPH oxidase activity, generation of ROS and
TBARS, byproducts of lipid peroxidation in the kidney, suggest that ROS/lipid peroxides
generated by renal and immune cells by AA most likely contribute to renal dysfunction,
inflammation, and end organ damage. Supporting this view are the reports that a)
monocytes/macrophages and T cells express cPLA2α273 and NADPH oxidase,241,294,295 b)
AA is required for activation of NADPH oxidase and generation of ROS in
monocyte/macrophages and VSMCs,12,241,294 and c) ROS and/or one or more AA
metabolites stimulate release of cytokines that promote inflammation.296,297
In conclusion, this study demonstrated that cPLA2α is essential for the
development of renal dysfunction, inflammation, and end organ damage associated with
Ang II-induced hypertension. AA released by cPLA2α activation by Ang II, most likely
via generation of pro-hypertensive eicosanoids, and ROS/lipid peroxides promote renal
dysfunction, activation of immune cells leading to inflammation, and end- organ damage.
Therefore, cPLA2α could serve as a potential novel target for developing therapeutic
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agents for treating hypertension and associated renal dysfunction and end organ damage.
Moreover, the development of water-soluble selective cPLA2α inhibitors would allow
further assessment of its physiological and pathophysiological significance in kidney
diseases and other models of hypertension
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CHAPTER 6.

CONCLUSION

This study has demonstrated that cPLA2α is essential for the development of Ang
II-induced hypertension and associated cardiovascular remodeling, cardiac and
endothelial dysfunction, and increased vascular reactivity. Cardiac oxidative and ER
stress and inflammation associated with Ang II-induced hypertension also depends on
cPLA2α. Ang II-induced cardiac dysfunction, remodeling, and inflammation that depend
on cPLA2α are most likely mediated by ERK1/2 and cSrc. My study provides novel
information on the mechanism of Ang II-induced hypertension and associated
cardiovascular pathophysiological changes, whereby cPLA2α-generated AA is crucial for
Ang II-induced hypertension.
These findings also suggest that cPLA2α gene disruption in mice minimizes Ang
II-induced increase in renal vascular resistance and renal dysfunction, inflammation, and
end organ damage.cPLA2α gene disruption also prevents the effect of Ang II to increase
renal NADPH oxidase activity, ROS, and TBARS production. cPLA2α plays a critical
role in renal dysfunction, inflammation, and end-organ damage associated with Ang IIinduced hypertension, most likely as a result of release of AA and generation of prohypertensive eicosanoids and ROS/lipid peroxides.
This study and the work of other investigators that has been discussed in this
dissertation has led us to propose the following mechanism of cPLA2α dependent Ang IIinduced hypertension and associated pathophysiology. (Figure 6.1) AA and or its
metabolites generated via cPLA2α, activates the immune system resulting in immune cell
infiltration and inflammation in cardiovascular and renal tissues. Cytokines released by
these infiltrating cells, results in elevation of BP and also ROS production. The
metabolites of AA may also cause ER stress which is known to promote ROS production
resulting in hypertension. ROS, via activation of second messenger systems, ERK1/2 and
cSrc results in cardiovascular and renal hypertrophy and dysfunction promoting
hypertension. Hypertension may in turn exacerbate end organ dysfunction and damage.
These observations raise the possibility that cPLA2α could serve as a target for
developing novel therapeutic agents to treat hypertension and associated renal
dysfunction and end organ damage.
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Figure 6.1
Proposed mechanism of cPLA2α dependent Ang II-induced
hypertension and associated pathophysiology
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